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Abstract 
Alternative splicing (AS) is a common post-transcriptional process in eukaryotic 
organisms, by which multiple distinct functional transcripts are produced from a single 
gene. Because of its potential role in expanding transcript diversity, interest in alternative 
splicing has been increasing over the last decade, ever since the release of the human 
genome draft showed it contained little more than the number of genes of a worm. 
Although recent studies have shown that 94% human multi-exon genes undergo AS while 
aberrant AS may cause disease or cancer, evolution of AS in eukaryotic genomes remains 
largely unexplored mainly due to the lack of comparable AS estimates. In this thesis I 
built a Eukaryote Comprehensive & Comparable Alternative Splicing Events Database 
(ECCASED) based on the analyses of over 30 million Expressed Sequence Tag (ESTs) 
for 114 eukaryotic genomes, including protists (22), plants (20), fungi (23), metazoan 
(non-vertebrates, 29) and vertebrates (20). Using this database, I addressed two main 
questions: 1) How does alternative splicing relate to gene duplication (GD) as an 
alternative mechanism to increase transcript diversity? and 2) What is the contribution of 
alternative splicing to eukaryote transcript diversity? I found that the previous 
“interchangeable model” of AS and gene duplication is a by-product of an existing 
relation between gene expression breadth, AS and gene family size. I also show that 
alternative splicing has played a key role in the expansion of transcript diversity and that 
this expansion is the best predictor reported to date of organisms complexity assayed as 
number of cell types. In addition, by comparing alternative splicing patterns in cancer and 
normal transcript libraries I found that cancer derived transcript libraries have increased 
levels of “noisy splicing”.  
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1. Introduction  
Alternative splicing (AS) is a post-transcriptional process in eukaryotic organisms 
by which multiple distinct transcripts are produced from a single gene (Graveley 2001). 
Recent studies using high-throughput sequencing technology have reported that up to 
92%~94% of human multi-exon genes undergo AS (Pan et al. 2008; Wang et al. 2008), 
and AS has been proposed to be a major factor in expanding the regulatory and functional 
complexity, transcript diversity and organismal complexity of higher eukaryotes (Nilsen 
and Graveley 2010). Alternative splicing patterns are also frequently tissue/development-
specific (Stamm et al. 2005; Wang et al. 2008), working independently of transcription 
regulation and providing an additional level of flexible control of gene expression 
(GE)(Artamonova and Gelfand 2007). Furthermore, both experimental and bioinformatics 
studies have shown that AS generates a variety of message RNA (mRNA) and protein 
products displaying distinct stability properties, subcellular localization and function 
(Stamm et al. 2005) thereby playing important roles in cell differentiation (Heinzen et al. 
2008), sex differentiation (Blekhman et al. 2010; Hartmann et al. 2011) and development 
(Stamm et al. 2005), while aberrant AS may lead to cancer and disease (Venables et al. 
2009; Watson and Watson 2010).  
In the following sections I will briefly describe how alternative splicing was first 
discovered and the current understanding of this process and its regulation. I will then 
describe how AS is measured and what is known about its evolution and its role in 
physiological states and disease.  
1.1 Alternative splicing 
In 1977, Chow et al. reported that 5′ and 3’terminal sequences of several 
adenovirus 2 (Ad2) mRNAs varied, implying a new mechanism that the diversity of 
splicing patterns and the variety of recombined sequences generated during the synthesis 
of late Ad2 mRNAs, following this study, alternative splicing was also found in the gene 
encoding thyroid hormone calcitonin in mammalian cells (Berget et al. 1977; Chow et al. 
1977; Alt et al. 1980; Early et al. 1980). Subsequent studies revealed that many other 
genes were also able to generate more than one transcript by cutting-out different sections 
from their coding regions (reviewed in (Graveley 2001; Artamonova and Gelfand 2007)).  
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Two decades after the discovery of alternative splicing, the first draft of the 
human genome sequence (Lander et al. 2001; Venter et al. 2001) was unveiled in 
February 2001 by two rival teams (the first an international consortium and the second, 
released by the private company CELERA). This draft of the human genome surprised 
academics as it showed our genome to contain ~23000 genes, only a fraction of the 
numbers of genes originally predicted (Crollius et al. 2000). In 2005, “Why the human 
genome has so few genes?” made it to the list of 25 top unanswered questions in science 
(http://www.sciencemag.org/site/feature/misc/webfeat/125th/), which drew much 
attention to alternative splicing given its potential to increase transcript diversity. With 
the development and subsequent constant improvement of whole genome transcription 
profiling and bioinformatics algorithms, the scale of occurrence of alternatively spliced 
transcripts began to become clear. Initial whole genome analyses suggested that 5%-30% 
percent of human genes were alternatively spliced. However, over the last ten years this 
number has been revised over and over with the latest estimates showing that up to 95% 
percent of human multi-exon genes produce more than one transcript through alternative 
splicing (reviewed in (Artamonova and Gelfand 2007)). The concept of one gene coding 
many proteins and prevalence of alternative splicing were gradually accepted as evidence 
mounted on the high percentage of AS incidence in human, mouse (Artamonova and 
Gelfand 2007) and other eukaryotes (Kim et al. 2007b). 
 
1.2 Alternative splicing and its regulation 
Splicing of precursor mRNA (pre-mRNA) is an essential step of gene expression 
in eukaryotes. Gene expression of protein-coding genes, the passage of information from 
the DNA gene sequence in a chromosome to the making of a protein- can be divided into 
two stages: transcription and translation. The process of transcription is controlled by 
transcription factors which bind in or near the promoter region, leading to the recruitment 
of RNA polymerases that copy the DNA nucleotide sequence into RNA. This RNA 
sequence contains a copy of the complete gene protein-encoding region (pre-mRNA) that 
contains both exons (sections which encode the sequence of amino acids in a protein) and 
introns (intervening segments which are removed or “spliced out” before the protein is 
produced). In the next stage, splicing is initiated by a complex of RNA-binding proteins 
known as the spliceosome, which catalyse the removal intron sequences of the pre-
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mRNA. The recognition of intron-exon boundaries is facilitated by the detection of small 
sequence motifs called splicing sites. At the same time another process called 
polyadenylation (poly-A), which refers to the addition of a poly-adenine tail to an 
untranslated region located in the 3´-terminal end of the last exon, is initiated by a 
polyadenylating enzyme. Once the pre-mRNA has been processed by splicing and 
polyadenylation, the resulting mature mRNA is transported out of the nucleus into the 
cytoplasm where translation of mRNA occurs by the decoding machinery (the ribosomes) 
resulting in the assembling of a distinct polypeptide.  
Splicing is tightly regulated by cis elements within exons and surrounding introns 
as well as trans-acting factors that bind to these cis element. Alternative splicing is an 
important mechanism of genetic control and its regulation is part of a complex network of 
regulatory events at different levels.  Here I will describe different aspects of alternative 
splicing regulation.  
In general, alternative splicing is thought to be controlled by RNA binding 
proteins that modulate the activity of the spliceosome which is composed of up of 5 small 
nuclear ribonucleoproteins (snRNPs) and more than 150 additional proteins. Besides the 
core components of the spliceosome, classic models of alternative splicing regulation also 
involve auxiliary splicing factors-proteins that are Serine/arginine-rich proteins (SR 
proteins) and heterogeneous nuclear ribonucleoproteins (hnRNP) proteins. SR proteins 
typically bind to exonic splicing enhancers (ESEs), where they interact with and recruit 
various components of the spliceosome such as U2AF to enhance 3´ splice site (3´ss) 
recognition and interact with U1-70K and recruit the U1 small nuclear RNP (snRNP) to 
process the adjacent 5´ splice site (Chen and Manley 2009; Graveley 2009). By contrast, 
hnRNP proteins tend to bind to exonic splicing silencers (ESSs) or intronic splicing 
silencers (ISSs) and repress splicing by other mechanisms (Chen and Manley 2009). For 
instance, hnRNP proteins prevent U2AF function by binding to the polypyrimidine tract. 
Also, hnRNP may bind to ISSs in the introns flanking an exon and looping the exon out 
of the pre-mRNA (Graveley 2009). Alternative splicing has also been shown to be 
regulated without the involvement of auxiliary splicing factors (Yu et al. 2008), 
suggesting the existence of additional non canonical mechanism of alternative splicing 
that are yet to be identified (Graveley 2009).  
The regulation of alternative splicing is a multifactorial process also related to 
other types of events, such as, initiation of transcription from alternative promoters and 
alternative polyadenylation. Alternative mRNA isoforms may be subject to different 
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regulation by internal translation initiation sites, RNA editing, mRNA decay and 
microRNA binding (Hughes 2006). Recently, a direct role of histone modifications in 
alternative splicing has been reported, in which histone modification affect the splicing 
outcome by influencing the recruitment of splicing regulators via a chromatin-binding 
protein in a number of human genes (Luco et al. 2010). Additionally, non-coding RNAs 
also have emerged as key determinants of alternative splicing patterns (Luco and Misteli 
2011) therefore revealing  an additional layer in the regulation of alternative splicing. 
Recently, a machine-learning method based on the splicing code has been shown to 
predict tissue-specific expression with high efficiency (Barash et al. 2010), providing 
novel tools and methods  of studying and predicting the outcome of alternative splicing. 
 
 
 
 
Figure 1: The splicing code. a. A exon/intron structure of pre-mRNA.  b. A 
schematic of regulated splicing. Exons (boxes), introns (solid line). Splicing is 
regulated by cis-elements (ESE, ESS, ISS and ISE) and trans-acting splicing factors 
(SR proteins, hnRNP, and unknown factors). The 5’ splice site (5’ss) and branch site 
serve as binding sites for the RNA components of U1 and U2 small nuclear 
ribonucleoprotein (snRNPs), respectively. This RNA base pairing determines the 
precise joining of exons at the recognition. This figure is adapted from (Wang and 
Cooper 2007b).  
 
  
Depending on either the location of the exonic segments cut out or if introns are left in, 
AS events can be classified into five basic types (Figure 1). These five major modes of 
AS are: (1) Exon skipping (2) alternative donor site (5’ ss), (3) alternative acceptor site 
(3’ss) (4) intron retention and (5) mutually exclusive exons (Ast 2004). In addition, 
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alternative initiation and alternative polyadenylation provide two other common 
mechanisms for generating various transcript isoforms. Moreover, different types of 
alternative splicing can occur in a combinatorial manner and one exon may be subject to 
more than one AS modes, for example, 5’ss and 3’ss at the same time. Differences in the 
relative prevalence of AS modes exist among different taxonomic lineages. For example, 
one comparative genomics study has shown that relative prevalence of the different types 
of AS varied from plants to metazoan, in which plants have higher level of intron 
retention while that of metazoan tend to be exon skipping (Kim et al. 2007a). 
 
 
 
 
Figure 2: Different types of alternative splicing. The green boxes are constitutive 
exons and alternatively spliced regions in red. Introns are represented by straight 
lines between boxes and other lines indicate splicing activities. This figure is adapted 
from (Lu et al. 2011). 
 
 
 
1.3 Measuring alternative splicing 
Alternative splicing is difficult to estimate from genomic parameters (Barash et al. 
2010). Regulatory motifs for alternative splicing are only now beginning to be uncovered 
and even the presence of these motifs may not guarantee that a gene is alternatively 
spliced (Barash et al. 2010). Accordingly, alternative splicing patterns have to be assessed 
from examining transcript data. For any alternatively spliced gene of interest, reverse 
transcription polymerase chain reaction (RT-PCR) can be conducted from a 
complementary DNA (cDNA) library in a specific tissue or development stage. A pair of 
forward and reverse PCR primers can be designed to target the flanking exons of a 
particular alternatively spliced exon. After the RT-PCR reaction, PCR products of 
different sizes corresponding to distinct mRNA isoforms can be separated and visualized 
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by electrophoresis. Combined with the use of radioactive or fluorescent labeling of PCR 
products (e.g. Quantitative PCR or Real-time PCR), this approach is highly sensitive and 
accurately reflects the splicing levels of individual exons. The main disadvantage of his 
method, however, is its low throughput level, making it suitable for detection or 
validation of a small set of genes rather than large-scale analyses. Over the last decade as 
high throughput transcriptome assessment technologies have improved, it has become 
possible to assess alternative splicing patterns on a genome wide scale. Three main 
sources of transcriptome data have been used to assess splicing patterns: expressed 
sequence tags (ESTs), splice-junction microarrays, and RNA-seq.  
The first wave of genome-wide analysis of whole transcriptomes consisted in 
direct sequencing cDNA and ESTs carried out at large scale (Sayers et al. 2009). 
Alternative splicing events can be identified by aligning cDNA/EST sequences to the 
reference genome. In order to analyze alternative splicing in any RNA sample of interest 
in a global and quantitative manner, splice-junction microarrays and RNA-Seq were 
developed. Splicing microarrays target specific exons or exon-exon junctions with 
oligonucleotide probes. The fluorescent intensities of individual probes reflect the relative 
usage of alternatively splicing exons in different tissues and cell lines (Johnson et al. 
2003). High-density splice-junction microarrays are a cost-effective way to assay 
previously known exons and alternative splicing events with low false positive rate. The 
drawback is that it requires prior knowledge of existing AS variants and gene structures. 
More importantly unlike RNA-Seq and EST, microarrays do not provide additional 
sequence information. In this thesis we have opted out from using data from splice-
junction microarrays due to above-mentioned reasons apart from its limited data 
availability for different species (Blencowe 2006). 
RNA-Seq has emerged as a powerful technology for transcriptome analysis due to 
its ability to produce millions of short sequence reads (Wang et al. 2009; Robertson et al. 
2010; Martin and Wang 2011). Briefly, the protocol of RNA-Seq consists of the 
following steps (i) polyadenylate RNAs, (ii) convert into randomly sheared cDNA, (iii) 
select size of sheared fragments, (iv) amplify and ligate adapters to fragments and finally 
(v) sequence the fragments using next generation sequencing (NGS). Reads can be 
obtained from only one end of a fragment (single-end sequencing) or from both ends of a 
fragment (paired-end sequencing). RNA-Seq experiments provide in-depth information 
on the transcriptional landscape with high sensitivity and scale (Wang et al. 2009). The 
ever increasing accumulation of high throughput data will continue to provide ever richer 
14 
opportunities to investigate further aspects of AS such as low-frequency AS events as 
well as tissue-specific and/or development-specific AS events (Pan et al. 2008; Wang et 
al. 2008; Martin and Wang 2011; Ozsolak and Milos 2011). 
ESTs are short (200–800 nucleotide bases in length), unedited, randomly selected 
single-pass sequence reads derived from cDNA libraries (Nagaraj et al. 2007). To obtain 
ESTs, mRNA sequences from expressed genes are first reverse transcribed to double-
stranded complementary DNA (cDNA), which is further cloned to make cDNA libraries 
that represent a set of expressed mRNAs of the original cell or tissue. These cDNA clones 
are sequenced at random from both directions in a single-pass run of the polymerase. 
Currently, there are eight million ESTs for human (including 0.9 million sequences from 
cancer tissues) and about 71 million ESTs for around 2000 species (Boguski et al. 1993). 
I have chosen this data source for all the analyses presented in this thesis for two main 
reasons: First, ESTs still provide on average longer transcript segments than most 
publicly available RNA-seq data; splicing junction microarray data, on the other hand, do 
not provide any sequence information and available data is restricted to fewer species. 
Second, compared with both splice-junction microarray data and RNA-seq, EST data on 
public repositories are more abundant and comprehensive in terms of tissues and species 
covered so far. Regardless of the advantages of using EST data, we are fully aware of 
theis limitations given in that they are based on Sanger sequencing and are aggregated 
over a wide range of tissues, developmental states and diseases using widely different 
levels of sensitivity. We are expecting to update our AS database and test evolutionary 
hypotheses in a global and quantitative manner using RNA-seq in the near future 
(Hawkins et al. 2010; Martin and Wang 2011; Ozsolak and Milos 2011). 
1.4 Alternative splicing in disease 
Alternative splicing is essential for normal cellular functions. However, the cis- 
and trans-acting mutations, that disrupt the splicing code or the machinery required for 
splicing and its regulation, are known to cause disease (reviewed in (Brinkman 2004; 
Venables 2006; Wang and Cooper 2007b; Venables et al. 2009)). It has been estimated 
that 15-60 % of mutations that cause disease by affecting the splicing pattern of genes 
(Lopez-Bigas et al. 2005) (Wang and Cooper 2007b). 
Specific mechanisms causing altered splicing have been described to fall within 
the following broad categories (Wang and Cooper 2007b; Jensen et al. 2009):  (1) 
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disruption of the splicing code. The majority of disease-causing splicing mutations affect 
critical cis splicing regulatory signals such as mutations of the consensus splicing site 
sequences at particular exon-intron boundaries creating cryptic splice sites, or altering the 
secondary structure or regulatory complex-binding regions including splicing 
enhancer/silencer elements within exons or introns (Wang and Cooper 2007b). However, 
due to the complexity of splicing code, we are still a long way from accurately predicting 
whether a mutation or genetic variation will disrupt the splicing code and alter splicing 
patterns (Lu et al. 2011). (2) Disruption of splicing machinery. Disease-causing splicing 
mutations can act in trans as well. For example, frequent mutations of splicing pathway 
machinery were reported in myelodysplasia, providing the first evidence indicating that 
genetic alterations of the major splicing components could be involved in human 
pathogenesis also implicating a novel therapeutic possibility for myelodysplasia (Yoshida 
et al. 2011). (3) RNA gain of function, which is caused by trans-dominant effects on 
splicing regulation. For instance, repeated 3-10 nucleotides within coding regions expand 
beyond pathogenic thresholds cause microsatellite-expansion disorders (reviewed in 
Wang and Cooper (2007)). (4) Disease-specific AS events. Several studies have explored 
cancer related changes in alternative splicing patterns (reviewed in (Kalnina et al. 2005; 
Venables 2006; Skotheim and Nees 2007; Wang and Cooper 2007a)) resulting in the 
identification of an increasing number of cancer-specific AS events in a variety of cancer 
tissues, and these disease-specific AS changes have been proposed to play an important 
role in cancer development (Wang et al. 2003; Xu 2003; Hui et al. 2004; Kim et al. 
2008a; He et al. 2009). 
1.5 Prevalence of alternative splicing across eukaryotic 
genomes 
Alternative splicing has been the subject of increased interest over the last few 
years with at least two whole genome studies in human having been published in quick 
succession (Pan et al. 2008; Wang et al. 2008). The number of species with reported AS 
events has continually increased over the years with instances of alternative splicing 
reported in plant and fungal species (Artamonova and Gelfand 2007; Kim et al. 2007a) 
demonstrating that AS appeared early in the evolution of eukaryotes. How prevalent 
alternative splicing is across different taxa and how alternative splicing patterns have 
changed and evolved through time, however, remains poorly understood. In fungi, AS is 
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thought to be rare due to the low number of introns in yeast (Ast 2004). In plants it has 
been estimated that around 20% of genes undergo AS (Wang and Brendel 2006). A better 
understanding of how alternative splicing has changed over time could provide a better 
understanding of how alternative splicing has impacted on transcript and therefore 
transcript diversity and phenotypic complexity (Nilsen and Graveley 2010). A few studies 
have attempted to compare alternative splicing prevalence between species with animals 
generally reported to have higher AS incidence than plants (Artamonova and Gelfand 
2007) and vertebrates having a higher AS incidence than invertebrates (Kim et al. 2007a). 
The fact that alternative splicing identification rates is highly sensitive to transcript 
coverage (Kim et al. 2007a) (Brett et al. 2002) (Kan et al. 2002), makes it difficult to 
assess how alternative splicing prevalence varies across taxa (Nilsen and Graveley 2010). 
In order to systematically assess AS prevalence among different taxa, I created a database 
for 114 species of fully sequenced eukaryotes with at least 30000 ESTs available per 
species. 
1.6 Structure of the thesis 
Alternative splicing can modulate gene function, affect organismal phenotype and 
is widespread in eukaryotes but, how did it originate and evolve? Our understanding of its 
evolution is limited and comparative genomics of alternative splicing becomes critical in 
answering this question. In Chapter 2, I present the Eukaryote Comprehensive & 
Comparable Alternative Splicing Events Database (ECCASED), a new AS event database 
web resource. In addition to identifying as many AS events as possible, I also created an 
AS index which was comparable among genes within a species and between species with 
different transcript coverage. There are a number of databases which provide multispecies 
AS data (Kim et al. 2007b; Lee et al. 2007; Wang and Burge 2008; Bhasi et al. 2009; 
Koscielny et al. 2009b). However, these existing resources primarily focused on animal 
species given the poor coverage for protist, fungal and plant genomes. In addition none of 
these resources allow for comparative analyses of AS as they fail to correct for 
differential transcript coverage among genes within and among species. These biases 
result from the fact that for any two genes producing an equal number of AS isoforms, the 
more sequences there are available for one of them, the more likely it is to sample a more 
complete set of AS transcripts. Based in the ECCASED database, I was able to address a 
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number of fundamental questions on alternative splicing and its role in the eukaryotic 
transcriptome that are explored in consecutive Chapters. 
 Gene duplication and alternative splicing are two main contributors to transcript 
diversity. On the one hand, gene duplications create new duplicated genes and evolve 
functional divergence (Long et al. 2003), driving the evolution of developmental and 
morphological complexity in vertebrates (Dehal and Boore 2005). On the other hand, 
alternative splicing, as a common post-transcriptional process in eukaryotic organisms, 
has been proposed as a potential mechanism for the production of multiple transcripts 
encoding proteins with functional differences from a single gene (Graveley 2001; Nilsen 
and Graveley 2010). In Chapter 3, I explore how alternative splicing relates to gene 
duplication by testing the relationship between gene family sizes and AS levels and 
different AS levels in 17 species from plants to mammalians. In Chapter 4, I focus on 
how alternative splicing has contributed to proteome expansion and phenotypic 
complexity over 1400 million years.  
Given the high number of AS events unique to cancer transcriptomes, cancer-
specific transcripts have been proposed to play a key role in cancer physiology (Skotheim 
and Nees 2007; He et al. 2009). A number of studies however have shown that a 
significant proportion of AS transcripts are likely to be the result of alternative splicing 
noise and are unlikely to produce a functional protein (Green et al. 2003; Lewis et al. 
2003; Zhang et al. 2009; Pickrell et al. 2010). Whether splicing events specific to cancer 
genomes are likely to contribute to cancer onset or cancer maintenance have not been 
explored in any depth. In chapter 5, I explore the likelihood of cancer-specific AS events 
being functional in the cancer transcriptome. 
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2 ECCASED: Eukaryotic Comprehensive and 
Comparable Alternative Splicing Events Database 
for 114 eukaryotic species 
2.1 Introduction 
Alternative splicing (AS) is a common post-transcriptional process in eukaryotic 
organisms by which multiple distinct functional transcripts are produced from a single 
gene by selectively cutting out segments from RNA transcripts (Graveley 2001). AS 
plays a key role in the regulation of transcript diversity in eukaryotic genomes with over 
92%~94% of human multi-exon genes now known to undergo AS (Pan et al. 2008; Wang 
et al. 2008). The dramatic increase of fully sequenced genomes and transcript data 
availability (Boguski et al. 1993) opens up the opportunity to assess AS patterns for genes 
within and across species providing insights into the evolution of AS (Artamonova and 
Gelfand 2007), transcript diversity and the evolution of complexity (Nilsen and Graveley 
2010). 
There are a number of databases that provide AS data for multiple species (Kim et 
al. 2007b; Lee et al. 2007; Bhasi et al. 2009; Koscielny et al. 2009a). However, these 
existing resources are primarily focused on animal species and have poor coverage for 
protist, fungal and plant genomes. Most importantly, none of these resources take into 
account the effects of differential transcript coverage across genes within and between 
species which greatly influences AS detection rates (Brett et al. 2002; Kan et al. 2002; 
Kim et al. 2007a; Nilsen and Graveley 2010).  
Here we present a Eukaryote Comprehensive & Comparable Alternative Splicing 
Events Database (ECCASED) based on the analysis of 39,620,288 EST transcripts 
available at dbEST (Boguski et al. 1993) for 114 eukaryotic genomes, including protists 
(20), plants (20), fungi (23) and metazoans (51, including 18 vertebrates). Using a 
uniform pipeline across all species, ECCASED is the most comprehensive database 
available to date in terms of the number of species covered and transcripts analyzed. 
Unlike other resources, ECCASED also provides a comparable AS index based on 
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random sampling allowing direct comparisons of AS in genes within and between 
species.  
 
2.2 Materials and methods 
Genome sequences, gene annotations and transcript data were downloaded from 
several publicly available genomic data sources during May 2011 (for a full list of data 
sources per species see Supplementary Table 1 at 
http://bio.bdfield.com/eccased/downloads.php). 
To identify AS events, the following analysis pipeline was used (see Figure 1):  
(i) EST to gene matching. Each EST was aligned against the corresponding  
genome sequence for its species using Genomic Mapping and Alignment Program 
(GMAP) software (Wu and Watanabe 2005). ESTs were required to align to the genome 
sequence with at least 95% identity and 95% coverage of its length; those which failed 
this requirement were removed from further analyses. Each EST was associated to their 
best hit according to identity and coverage as provided by the GMAP software (Wu and 
Watanabe 2005). ESTs matching to regions with no annotated genes were discarded from 
further analyses. Any ESTs with a best hit to a region with an annotated gene (from start 
of first to end of last exon) was assigned to that gene. All annotated overlapping genes, 
including any instances of nesting and their matching ESTs were also removed from 
further analyses. Genes with no matching transcripts were removed from the AS 
identification pipeline but all other gene annotations and functional classifications were 
retained for database construction. All ESTs from cancer-derived EST libraries were 
removed from further analyses. 
(ii) Template building. To obtain an exon template as complete as possible (as 
well as overcoming the fact that some invertebrates do not have full transcripts 
sequenced) all available ESTs for a given gene were overlaid onto its genomic sequence 
(Figure S1A and S1B). First the longest partial or full transcript available forms the base 
of the template. All other mRNAs and ESTs are then aligned to the genomic sequence 
and boundaries with the previously included transcripts are revised to extend exons or 
include new ones. If a transcript only encompasses a single exon then it will be discarded. 
This allows identifying and discarding any single exon nesting genes that have not been 
previously annotated.  
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Over 35000 exons across all species which were supported by fewer than 5 
percent of ESTs available for any given gene were removed from further analyses to 
avoid inclusion of exons resulting from splicing errors. 
(iii) Detection of AS events. Exon boundaries for each EST (obtained from GMAP 
alignments) were compared to its corresponding gene template (Figure S2) to identify AS 
events. AS events were classified into 8 different types (classification adapted from 
(Malko et al. 2006); Figure S2). For the purpose of counting AS events per gene, any AS 
events with coordinates differing by less than 15bp were considered as one. This is 
because the algorithm used by GMAP depends on an 8-mers finding clusters algorithm 
(Wu and Watanabe 2005). Coordinates of all AS events identified in each EST are 
available as bulk downloads per species. 
(iv) Calculating comparable AS indexes. In addition to AS event counts from all 
ESTs available per gene, we also obtained a comparable index which avoids biases due to 
differential transcript coverage. For this, the average number of AS events in 100 
randomly selected samples of 10 ESTs was calculated for all genes with over 10 
associated ESTs (Kim et al. 2007a). It is important to note that the comparable index is 
not intended to reflect the number of AS events per gene but instead the number of AS 
events found per 10 ESTs. 
(v) Identification of AS isoforms. To identify AS isoforms, ESTs with at least one 
AS event were first sorted according to the number of AS event they contain. Then ESTs 
containing identical or similar AS events were classed as redundant and excluded from 
the analysis. The number of remaining ESTs was taken as estimate of AS isoforms 
produced per gene. Result tables contain coordinates and EST support numbers for each 
AS event. AS event annotation per EST are provided in the download files. 
Additional data including Gene ontology terms, gene description and homologous 
relationships were retrieved from BioMart (Haider et al. 2009) for 71 species. For the 
remaining 43 species not currently supported by Biomart orthology relationships were 
assessed using the InParanoid software (Berglund et al. 2008). EST expression 
annotations were retrieved from EST library information contained in the dbEST bulk file 
(Boguski et al. 1993). 
The ECCASED database is in accordance with the format of BioDBcore 
(http://biocurator.org/biodbcore.shtml). 
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Figure 1. Overview of the ECCASED database building pipeline. Starting from 
genomic and EST transcript sequences and gene coordinates (see supplementary 
Table 1 for sources), individual ESTs were matched to specific genes. After 
producing a full template of intron/exon coordinates, AS events were detected in 
either all ESTs available per gene or within 100 samples of 10 transcripts. Unique 
AS events and isoforms were identified by removing redundant transcripts 
containing AS coordinates differing by less than 15bp from each other. Gene 
ontology annotations and gene orthology relationships are integrated to AS 
comprehensive and comparable data (see methods for further details). 
 
2.3 Results 
2.3.1 The ECCASED database  
In total, 39,449,472 ESTs were analyzed to identify instances of AS events 
corresponding to 811,940 genes out of a total of 2,432,032 annotated genes in 114 species 
analyzed including 23 fungi, 20 protists, 20 plants and 51 metazoans including 18 
vertebrates (see methods and Figure 1). A total of 1,140,498 unique AS events 
corresponding to 238,658 genes across all species were identified across all species (see 
methods and Supplementary Table 3). Importantly, while other EST based AS databases 
identify AS events in 40-60% of human genes (Kim et al. 2007b; Lee et al. 2007; Bhasi et 
al. 2009), we found that 97% of human multi-exon genes are alternatively spliced with 
>10 ESTs per gene, which is in line with recently reported high-throughput sequencing 
based studies (Pan et al. 2008; Wang et al. 2008). In other vertebrates, on average 89.4% 
were classed as undergoing AS, the highest rate reported to date (Kim et al. 2007b; Lee et 
al. 2007; Bhasi et al. 2009). 
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Table 1. Statistics summary for ECCASED 
 
Eukaryotic 
groups Species 
Annotated 
genes 
Genes 
with 
EST 
All AS 
genes 
Genes 
(>10 
ESTs) 
AS 
genes 
(>10 
ESTs)  
AS 
prevalence 
(>10 ESTs) 
% 
Fungi 23 258042 84982 7312 11080 3979 35.9 
Protists 20 399957 93087 6370 13669 3143 23.0 
Plants 20 709185 248710 72664 156238 52757 33.8 
Insects 15 258552 71558 14620 20947 10429 49.8 
Invertebrates 
(other) 18 406564 101394 19874 24252 12188 50.3 
Vertebrates 18 399732 212209 117818 101212 90505 89.4 
Total 114 2432032 811940 238658 327398 173001 52.8 
 
 
The ECCASED database represents the first assessment of alternative splicing 
patterns for approximately 70% of species analysed. The analysis of 20 plant genomes 
showed that more than 33.8% of genes undergo alternative splicing (Table 1 and 
Supplementary Table 3) compared to 20% in previous estimates based on a handful of 
species and using fewer transcripts (Wang et al. 2008). Interestingly, in fungal species 
where AS was previously thought to be rare (Ast 2004), we found evidence for AS events 
in 35.9% of genes with more than 10 ESTs (Table 1 and Supplementary Table 3). Protists 
were the group with the lowest overall AS incidence with just over a fifth of genes 
(23.0%) found to undergo alternative splicing (Table 1 and Supplementary Table 3). To 
our best knowledge, ECCASED is to date both the most comprehensive and the largest 
alternative splicing database of eukaryotic genomes. 
2.3.2 Comparable AS estimates 
There is a strong dependence of AS detection on transcript coverage across genes 
within and between species which has hampered the comparative analyses of AS patterns 
(Brett et al. 2002; Kim et al. 2007a; Nilsen and Graveley 2010). For example, while on 
average there are over 150 transcripts for every mouse gene, for its closely related species 
the rat there are, on average, little over 30 transcripts per gene. As a result, on average 
3.03 isoforms per gene are identified in mouse while in the rat the average number of AS 
isoforms detected is 1.70 (Supplementary Table 3). By using a random transcript 
sampling method to obtain comparable AS estimates (see methods), we minimize the 
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dependence between AS and the ESTs coverage within and across species, resulting in 
AS indexes more similar for closely related species regardless of differences in transcript 
coverage. In the case of mouse and rat, using the random sampling protocol, we obtained 
an average of 1.47 and 1.41 in each sample of 10 ESTs respectively. This comparable AS 
index is not a calculation of the total number of AS events in a gene but instead is an 
index of AS events per ten transcripts to allow a direct comparison of genes within a 
genome and for genes in different species with differing transcript coverage (Kim et al. 
2007a). Based on this comparable AS data, we also calculated the number of genes with 
at least one alternative splicing event in every ten ESTs. This AS prevalence index is 
likely to be an underestimation of AS prevalence as most genes produce many more 
transcripts however it allows for a direct comparison of relative differences in AS 
prevalence among species groups. We found that 90% of human genes have at least one 
on ten EST with alternative splicing evidence. Using the same comparative threshold we 
found that 21.3 of fungi, 13.0% of protist, 22.1% of plant, 33.5% of invertebrates and 
79.8 of vertebrate genes have at least one EST in ten with AS evidence. To further 
facilitate the comparative analyses of the AS data in the ECCASED database we 
integrated gene homologous relationships among 71 species from BioMart (Haider et al. 
2009). Homologous relationships for the remaining 43 species were generated using 
InParanoid software (Berglund et al. 2008) constituting, for many species, the first 
assessment of homology relationships. 
2.3.3 Web interface and output 
The ECCASED database can be consulted through a user-friendly web interface 
which provides: (i) AS summary statistics including the number of identified AS events 
and isoforms as well as AS comparable indexes based on random sampling analyses. 
Available transcript number is also provided (Figure 2A); (ii) exon information: genomic 
coordinates per exon as assembled de novo from the available ESTs, with supporting 
transcript number and AS event and ratio inside this exon. (iii) AS event listing with AS 
event genomic coordinates, type of AS event, transcript number evidence, and a 
representative transcript ID for each isoform with its expression information (a full list of 
mapping coordinates for AS events per EST is available for download); (iv) graphic 
genomic view showing gene template as well as representative transcript coordinates 
containing all AS events found per gene (Figure 2B); (v) homologous relationships along 
with AS statistics for each homologous gene (Figure 2C); (iv) gene ontology associated 
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terms for the gene. In addition, for users intending to use the database for genome wide 
studies, (v) bulk downloads of AS data per species or with genes divided according to GO 
terms are available. 
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Figure 2. Screenshot of the ECCASED page. From the top bar (A), Search modes, 
namely, gene identifiers, multiple genes, gene ontology and keywords can be 
selected. Links to downloads, readme files and contact instructions are also found 
here. Group and species restrictions can be applied by using drop down menus (B). 
Query output contains several tables: AS statistics (C) including comparable AS 
estimates; Exon information (D) which includes exon annotations with transcript 
support per exon and AS information; AS events (E) present coordinates, 
representative ESTs and its expression; genomic view (F) showing the gene template, 
representative ESTs for each AS isoform and alternatively spliced regions; AS 
summary statistics for homologous genes (G) and gene ontology annotations (H). 
 
2.3.4 Database mining and tool 
The ECCASED database can be queried in four main ways: 
(A) Gene identifiers. Ensembl gene IDs are used as primary identifiers for genes 
of 71 species with various source specific identifiers used for the remaining 43 (see 
Supplementary Table 1 for a full list of gene annotation source data, gene ID type and 
format). Gene symbol/gene name and Entrez IDs can also be used in most species. Users 
can search for individual or multiple genes and restrict the searches to individual species, 
a predefined list or by group (Fungi, Protists, Plants, Metazoans (non-vertebrates) and 
Vertebrates) (Figure 2). 
(B) Keywords (e.g. troponin) from gene descriptions. Advanced queries are also 
possible, for example, the query “+troponin –similar” will return every gene containing 
the keyword troponin but which does not contain the term similar on its gene description. 
By using double quotes, users can also specify the certain combination of word and 
character or number e.g. "troponin I".  
(C) Gene ontology IDs and terms. Searches by gene ontology keywords (from GO 
term or keyword in GO description) are also supported. As the some GO terms are 
associated with a high number of genes, GO searches are restricted to a single species at a 
time. AS statistics of genes in the queried GO category will be shown, and can be 
downloaded for further AS comparison among GO categories. 
(D) Bulk data download with AS events, AS statistics and gene template 
coordinates per species or by GO term are available. A more comprehensive download 
with mapping coordinates for AS events in each EST is also available. Users may request 
the AS identification software to analyze their own sequences. 
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2.4 Discussion 
ECCASED provides multiple-species alternative splicing analysis based on public 
data in May 2011. As more genomic data becomes available, we plan to update ESTs 
analyzed, exon/intron gene annotations, GO ontology as well as the functional annotation 
of AS event/isoform. We plan to provide functional annotations of predicted Open 
Reading Frames (ORFs) as well as putative functional domains within constitutive and 
AS regions. With the recent advent of next-generation sequencing technologies, we are 
aware of the importance of using high-throughput sequences from RNA-seq in our 
analysis. We plan to integrate short read data with EST data to be able to provide 
quantitative expression abundance data on a per AS-isoform basis. An expression pattern 
based search will also be included 
The ECCASED database covers 114 species with sequenced genomes making it 
the most comprehensive database to date. Unlike existing AS data resources, in addition 
to the listing of all identified AS events, the ECCASED database also provides a 
comparable AS index per gene avoiding the strong biases caused by differential transcript 
coverage in AS detection rates allowing direct contrast between genes within and across 
species. ECCASED data can be accessed in several ways from single gene analyses to 
bulk downloads to maximise appeal for a wide range of users and we expect this resource 
to facilitate future studies of alternative splicing patterns. 
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2.5 Supplementary Materials 
 
 
Figure S1. Exon template building. Panels A and B show gene templates for 
ENSMMUG00000000100 and 75624 from mouse and amphioxus, respectively. In 
both cases, the top line represents the chromosome region where the gene is located. 
The second line represents the resulting template from alignments of all available 
EST sequences. Note that exons supported by fewer than 5% ESTs for any given 
gene were disregarded as possible splicing errors. The following lines show the 
mRNAs and ESTs used to build the template. In the first example, by comparing 
two transcripts an exon segment was recovered (A). In the second example, a gene 
template was constructed from ESTs alone as no full length mRNA was available 
(B).  
28 
 
Figure S2. Identification of AS events. For each gene, AS events were identified by 
comparing individual transcripts against the template. In the diagram, constitutive 
exons are shown in black and AS events are shown in gray. Eight types of AS events 
were identified: Constitutive exon (C); Exon skipping (E); alternative 5’ donor site 
(D); uncertain edge 5’ donor site (uD); alternative 3’ acceptor site (A); uncertain 
edge 3’ acceptor site (uA); 3’ acceptor site and 5’ donor site (AD) and intron 
retention (I) (Malko et al. 2006). Splicing events with coordinates within 15bp of 
each other were considered to correspond to the same AS event. 
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3 Gene expression breadth explains the relationship 
between alternative splicing and gene duplication 
3.1 Introduction 
Both alternative splicing (AS) and gene duplication (GD) have been proposed to 
play important roles in the evolution of novel functions (Graveley 2001; Long et al. 2003; 
Dehal and Boore 2005; Nilsen and Graveley 2010). AS was once thought to be restricted 
to a small proportion of genes but recent studies have revealed that AS is prevalent in 
many eukaryote genomes (Artamonova and Gelfand 2007; Kim et al. 2007a) and in 
human 92%~94% of multi-exon genes undergo AS (Pan et al. 2008; Wang et al. 2008). 
A number of studies exploring how these two mechanisms relate to each other 
have consistently found a negative correlation between gene family size (GFS) and 
average AS events detected per gene in human, mouse (Kopelman et al. 2005; Su et al. 
2006; Jin et al. 2008) and worm (Hughes and Friedman 2008; Irimia et al. 2008). 
Singletons have been found to go against the inverse correlation by having lower 
alternative splicing than those gene families of two members (Jin et al. 2008; Roux and 
Robinson-Rechavi 2011) thus the negative correlation between AS and GFS may only 
apply to multi gene families. The correlation between AS and GFS has been explained as 
the result of the steady increase in alternative splicing per gene along time (Roux and 
Robinson-Rechavi 2011). The small number of species tested and diversity of datasets 
and methodologies used (Table S1), does not allow a comparison of findings for different 
species. Here, we systematically investigate the relationship between AS and GFS in 17 
species from different taxa and assess the role of expression measures in driving this co-
variance. 
  
3.2 Materials and methods 
3.2.1 Datasets 
Genome sequences and predicted genes were downloaded from databases shown 
in Table S2, and EST sequences were downloaded from UniGene (Sayers et al. 
2010)(ftp://ftp.ncbi.nih.gov/repository/UniGene/). 
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3.2.2 Identification of paralogs and orthologs 
Using the method from a previous study (Jin et al. 2008), we assembled gene 
families from sea urchin and amphioxus according to the alignment of protein sequences. 
For predicted genes from Ensembl, we extracted paralogs of each Ensembl gene family 
ID from BioMart (Haider et al. 2009) and calculated the gene family size by adding the 
number of the paralogs and the gene itself. To identify orthologous relationship for 
Ensembl genes, the orthologs were retrieved from BioMart (Haider et al. 2009). We 
defined 3879 gene families with one or more genes that were present in at least three 
invertebrate and three vertebrate species. To assess whether families associated with 
different functional categories tended to have a decreased, stayed stable, or increased in 
transcript diversity, we first assigned non-redundant GO slims (Harris et al. 2004)from 
human to each gene family and then obtained linear regressions between transcript 
diversity against time of divergence from human lineage. Gene families then were 
assigned to one of 4 blocks according to the slopes from linear regressions per family and 
divergence time (see methods): ‘decreased’ (slope < 0.0000); ‘stable’ (0.0000 =< slope < 
0.0015); ‘increased’ (0.0015 =< slope <= 0.0025); ‘highly increased’ (slope > 0.0025).  
3.2.3 Identification of alternative splice events  
To estimate AS events in different organisms, a novel procedure was applied as 
follows:  
(1) Mapping predicted genes and ESTs to Genome and grouping ESTs for each 
gene. Overlapping and nested genes were identified and removed from further analyses. 
GMAP (Wu and Watanabe 2005) was used to align full transcripts and high quality ESTs 
to their corresponding predicted genes. Genes with no matching transcript were removed.  
(2) Template building. To obtain a gene template as complete as possible (as well 
as overcoming the fact that some invertebrates do not have full transcripts sequenced) full 
transcripts and ESTs were overlaid onto the genomic sequence. This was done as follows: 
First the longest partial or full transcript available forms the base of the template. All 
other mRNAs and ESTs are then aligned to the genomic sequence and boundaries with 
the previously included transcripts are revised to extend exons or include new ones. If a 
transcript only encompasses a single exon then it will be discarded. This allows 
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identifying and discarding any single exon nesting genes that have not been previously 
annotated.  
(3) Detecting AS events and AS isoforms. We developed an algorithm to compare 
the exon boundaries of any transcript to its corresponding template. To identify AS 
isoforms, transcripts were first sorted according to the number of AS events they contain. 
Then transcripts containing identical or similar AS events were classed as redundant. In 
addition to the listing of all identified unique AS events, we also generated a comparable 
AS index that minimizes the effects of differential transcript coverage. For this, one 
hundred samples of 10 randomly selected transcripts were obtained, for genes with at 
least 11 associated ESTs, in every species (Kim et al. 2007a). AS event and isoform 
number were then calculated as described above in each sample and results were 
averaged across all 100 samples per gene.       
3.2.4 Gene expression data   
Gene expression data for UniGene were downloaded from NCBI ftp (Sayers et al. 
2010). We assign each EST to library according to its tissue, development state and 
whether it is from a cancer source or normal tissue. In this study, all libraries from cancer 
sources were excluded. In order to compare expression across species, we grouped library 
from different tissues into 10 common organ levels (http://bodymap.jp/organ_tissue_rule) 
that are comparable between species according to BodyMap-Xs (Ogasawara et al. 2006). 
In order to minimize the bias caused by different abundance (the number of ESTs) of the 
grouped libraries in the 10 common organs, we employed a random sampling to 
reconstruct the library, in which we randomly selected 10000 ESTs for 100 repetition 
(one million ESTs) from the pooled libraries of an organs, then counted how many times 
each gene present in this random sample of one million ESTs, which were used as a 
proxy of expression for each gene in different organs.   
For independent expression data, we downloaded gene expression data for 10 
species from BodyMap-Xs (Ogasawara et al. 2006). According to the corresponding table 
between Ensembl gene and UniGene, we joined UniGene expression data to Ensembl 
gene and remove any UniGene corresponding to more than one Ensembl gene. 
Microarray data in human and mouse (Su et al. 2004) and serial analysis of gene 
expression (SAGE) tag sequences in human were used (http://cgap.nci.nih.gov/SAGE). 
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Figure 1:  The comparison between the gene family size and the proportion of genes 
with AS and AS isoform index. Histogram bars indicate the fraction of genes 
containing more than one AS isoform (A) and the AS isoform index (B), classified as 
singletons (1 member) and small (2~3 members), medium (4~9 members) and large 
(>9 members) gene families.  
 
3.3 Results 
3.3.1 No universal negative correlation between gene family size and AS  
To investigate the relationship between AS events and gene duplication, gene family 
annotations were obtained for 17 species (for species list see Table S2) and AS events per 
gene were identified using publicly available ESTs and mRNAs (see methods). We then 
assessed the relationship between AS and GFS. We found significant inverse correlations 
for only seven of the 17 species analysed (P < 0.0029 after Bonferroni correction). 
Singletons have been previously found to have lower alternative splicing than multi-gene 
families (Jin et al. 2008; Roux and Robinson-Rechavi 2011) and have been suggested to 
have different evolutionary paths compared to multi-gene families (Jin et al. 2008) and to 
have a slower gain of alternative splicing events (Roux and Robinson-Rechavi 2011). 
Although we did not find the lower AS levels for singletons to be a consistent pattern 
(Figure 1 and Table S3), we reassessed the relationship between both variables after 
removing singletons. A significant negative correlation coefficient was obtained for a 
total of six species (P < 0.0029 after Bonferroni correction, see Table 1).  
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Table 1.  Correlation test between gene family size and AS occurrence in 17 species. 
 Organism 
All 
Genes P R Duplicates P R 
Oryza sativa 13616 4.87E-23 -0.0846 11008 2.08E-22 -0.0926 
Arabidopsis 
thaliana 12440 0.0048 -0.0253 10151 0.0548 -0.0191 
Caenorhabditis 
elegans 4519 0.0097 0.0385 2568 0.4647 -0.0144 
Drosophila 
melanogaster 5412 0.1038 0.0221 3012 0.0424 -0.0370 
Strongylocentrotus 
purpuratus 1039 0.1582 0.0438 493 0.9357 0.0036 
Branchiostoma 
floridae 1380 0.8334 0.0057 577 0.8991 0.0053 
Ciona intestinalis 5117 0.3056 0.0143 2925 0.0062 0.0506 
Danio rerio 8645 0.1074 0.0173 6385 0.8978 0.0016 
Gasterosteus 
aculeatus 1742 0.2690 0.0265 1290 0.7611 -0.0085 
Oryzias latipes 2817 0.0190 -0.0442 1817 0.0003 -0.0854 
Xenopus tropicalis 5265 0.0023 -0.0419 3560 0.0067 -0.0455 
Gallus gallus 5499 0.1697 -0.0185 3438 0.4509 -0.0129 
Sus scrofa 5281 1.30E-06 -0.0665 3345 0.0054 -0.0481 
Bos taurus 8420 1.08E-06 -0.0531 5794 1.99E-06 -0.0624 
Rattus norvegicus 7665 0.0013 -0.0368 5413 2.45E-07 -0.0701 
Mus musculus 13417 8.66E-22 -0.0827 9502 1.09E-37 -0.1311 
Homo sapiens 13290 1.97E-05 -0.0370 9298 5.19E-29 -0.1156 
 
A consistent downward trend in AS for larger gene families was not observed 
either when visually inspecting the data after dividing all gene families into four groups 
according to Kopelman et al. (2005): singletons; and families with 2~3, 4~9 and families 
with >9 members or when considering all families or multi-gene families only (Figure 1).  
Given the large differences in transcript coverage among genes and between 
species and the fact that alternative splicing detection is highly dependent on transcript 
coverage and could thus influence the relationship between gene family size and 
alternative splicing, we calculated a comparable index of alternative splicing using 
random samples of ten transcripts (see methods). Using this normalised AS data, we 
found similar results to those using the non-corrected AS values with 3 species for all 
genes and 7 species for duplicates found to have a significant negative correlation for AS 
and GFS (P < 0.0029 after Bonferroni correction; Supplementary Figure 1; Table S4). 
Our results show that the inverse relationship between AS and GFS is not universal. 
Furthermore, the previously reported lower AS values for singletons do not hold true for 
seven of 17 species analysed. It is worth noting that consistent with previous reports 
(Kopelman et al. 2005; Su et al. 2006; Jin et al. 2008), significant negative correlations 
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were observed for human and mouse but was not recovered in the nematode (Hughes and 
Friedman 2008; Irimia et al. 2008). 
 
 
 
Figure 2: Comparsion of the relationship beteen AS, GFS and breadth. The 
histogram bars indicate the correlation coefficient of AS versus GFS, GFS versus 
Breadth, AS versus breadth in nine species, respectively. 
 
3.3.2 The relationship between alternative splicing, gene family size and 
gene expression 
It has been reported that width of gene expression (number of tissues where a gene 
is expressed) is linked to the gain of transcript isoforms (Wegmann et al. 2008). In 
addition, there is a general trend for duplicated genes to become more specialized in their 
expression patterns, with decreased breadth and increased specificity of expression per 
gene as gene family size increases (Huminiecki and Wolfe 2004; Freilich et al. 2006; 
Farre and Alba 2010). It is therefore possible that the observed weak but significant 
relationships between GFS and AS observed in some species could be the by-product of 
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the relationship of both variables with breadth of expression. Thus, we first assessed the 
relationship between AS (normalised) and GDF with three measures of gene expression: 
peak, mean and breadth in nine of the 17 species studied for which expression data was 
available (see methods). We found a consistent positive correlation between the breadth 
of expression with AS in all species, while a negative correlation between the expression 
breadth and GFS (Figure 2). Significant correlations for AS and GFS were also observed 
in some but not all species (Figure 2). Given that all three expression measures highly co-
vary with one another (Lercher et al. 2002; Urrutia and Hurst 2003), we assessed whether 
all three were independently related to both AS and GFS. To do this, we performed 
forward stepwise tests where the contributions of the three measures of expression in 
predicting AS and GFS were tested. We found that breadth but not expression level 
(measured as peak and mean expression) is consistently correlated with both AS and GFS 
whereas peak and mean expression are only marginally related with AS and GFS in some 
species (Figure 3). Accordingly, analyses presented below focus on expression breadth 
only. 
 
 
 
Figure 3: Contributions of the three measures of expression in predicting AS and 
GFS. The left panel shows R-squared of stepwise between AS and breadth, peak and 
mean of gene expression. Breadth shows largest proportion of R-squared. The right 
panel presents R-squared of stepwise between GFS and breadth, peak and mean of 
gene expression. Breadth shows largest proportion of R-squared.  
 
To test whether the relationship between AS and GFS could be explained by the 
link of both variables with breadth, we performed forward stepwise analysis. We found 
gene expression breadth to be the best predictor for both AS and GFS. Notably, AS was 
not included as a relevant variable in the stepwise models predicting GFS in any of the 
nine species examined whereas GFS was included as a relevant variable with a marginal 
contribution in the stepwise tests as a predictor of AS for only three of the nine species 
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analysed (Figure 4). These results suggest that the significant and consistent covariance of 
breadth of expression with both AS and GFS largely accounts for previously reported 
inverse correlations between both AS and GFS. Similar results were obtained when using 
three other expression datasets covering some species: BodyMap-Xs (EST based 
expression data (Ogasawara et al. 2006)), Microarray data (Su et al. 2004) and SAGE 
data (NCBI) (supplementary Figure S2-S4).  
 
 
Figure 4: Gene expression breadth is the better predictor in the relation between AS 
and GFS. The right panel shows R-squared of stepwise between AS and breadth and 
GFS. Breadth shows larger proportion of R-squared than that in GFS. The left 
panel presents R-squared of stepwise between GFS and breadth and AS. Breadth 
shows larger proportion of R-squared than that in AS.  
3.4 Discussion 
Here we have showed that the previously reported inverse correlation between 
gene family size and alternative splicing (Kopelman et al. 2005; Su et al. 2006; Jin et al. 
2008) is not universal but constrained to some species regardless of whether the analyses 
is constrained to multi-gene families or not. In addition, no support was found for the 
previously reported lower rate of AS for singleton genes compared to multi-gene families 
(Jin et al. 2008; Roux and Robinson-Rechavi 2011). These observations remain 
unchanged even after correcting for variations in transcript coverage among genes and 
between species known to have a strong impact in AS detection (Brett et al. 2002; Kim et 
al. 2007a; Nilsen and Graveley 2010). 
In contrast, the relationship between AS and GSF with breadth of expression is 
consistently found in all species analysed with expression intensity marginally 
contributing to predicting AS and GFS in most species. We further found that any 
covariance between AS and GFS is largely explained as a by-product of the relationship 
of both variables with expression breadth. 
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Figure 5:  The relationship among gene expression breadth, alternative splicing and 
gene duplication. Consistent positive correlation were found between AS and 
breadth, in contrast, negative correlation were shown between breadth and gene 
duplication. Which possibly explain the negative effect between AS and gene 
duplication which leads to the increase of GFS. 
 
Over time, genes acquire novel alternative splicing isoforms (Kim et al. 2007a; 
Wegmann et al. 2008; Roux and Robinson-Rechavi 2011; Warnefors and Eyre-Walker 
2011) allowing them to specialize their function when expanding their expression to new 
tissues resulting in a positive correlation between AS and breadth of expression. Gene 
duplication events, in contrast, are often followed by the subfunctionalisation of both 
copies with each being expressed in fewer tissues than the ancestral single copy 
(Huminiecki and Wolfe 2004; Freilich et al. 2006; Farre and Alba 2010) and resulting in a 
negative correlation between gene family size and breadth of expression (Figure 5). We 
can expect a negative correlation between alternative splicing and gene family size only 
where a stable optimum ‘transcript diversity’ level exists. An expanding number of 
proteins throughout evolution for any given family can result from either an expansion in 
gene number, an expansion in alternative splicing isoforms or by an expansion of both. 
To test whether the relationship between AS and GFS differs for gene families with or 
without expanding number of transcripts throughout evolution, we calculated overall 
transcript diversity in over 3000 gene families (see methods) and divided them in three 
groups: expanded, stable and decreased transcript diversity. We found that those families 
with stable or decreased transcript diversity over time, exhibit a negative correlation 
between AS and GFS whereas for those gene families with an increased transcript 
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diversity the two variables are positively related (Figure 6). Interestingly, we also found 
that gene families with expanding, stable and decreasing transcript diversity are not 
distributed over all functional categories equally. Gene functions associated with cell-to-
cell communication, development and behavior are associated with increased transcript 
diversity (Figure 7). 
 
Figure 6:  The distribution of correlation coefficient of AS vs. GFS in three groups. 
The gene families were divided into different groups according to three fates of 
transcript diversity of gene family including maintain, increase and decrease. 
 
We conclude that alternative splicing and gene duplication far from being 
mutually exclusive mechanisms, are joint contributors of transcript diversity within gene 
families in close association with gene expression breadth. 
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Figure 5. Functional heterogeneity in proteome expansion. Relation between GO 
categories and changes in transcript diversity comparing 3879 gene families 
(presented in at least three invertebrate and three vertebrate species). Each row 
represents the gene families associated with each functional category; the height of 
each row represents the proportion of families associated with each functional 
category. Colours denote whether, for any given functional category, the number of 
gene families in a particular group or block is above expectations (blue), under 
expectations (red) or at expected levels (grey). Mosaic plots were adopted according 
to the webpage (http://www.statmethods.net/advgraphs/mosaic.html). The Chi-
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squared test was used for test the proportion among GO categories from four 
groups. 
 
3.5 Supplementary Materials 
 
Figure S1. The comparison between the gene family size and the AS event index. 
Histogram bars indicate the randomized AS index, classified as singletons (1 
member) and small (2~3 members), medium (4~9 members) and large (>9 members) 
gene families.  
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Figure S2: Comparison of the relationship between AS, GFS and breadth. The 
histogram bars indicate the correlation coefficient of AS versus GFS, GFS versus 
Breadth, AS versus breadth in nine species from BodyMap-Xs, respectively. 
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Figure S3:  Stepwise tests of AS, GFS and GE using BodyMap-Xs, SAGE and 
Microarray data in human. (A) R-squared of stepwise between AS and breadth, 
peak and mean of gene expression (GE). Breadth shows largest proportion of R-
squared. (B) R-squared of stepwise between GFS and breadth, peak and mean of 
gene expression. Breadth shows largest proportion of R-squared. (C) R-squared of 
stepwise between AS and breadth and GFS. Breadth shows larger proportion of R-
squared than that in GFS. (D) R-squared of stepwise between GFS and breadth and 
AS. Breadth shows larger proportion of R-squared than that in AS.
43 
 
 
Figure S4. Comparison of the relationship between AS, GFS and breadth. The 
histogram bars indicate the correlation coefficient of AS versus GFS, GFS versus 
breadth, AS versus breadth in human using BodyMap-Xs, SAGE and Microarray, 
respectively. 
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Table S1: Paper summary for the relationship between AS and GFS 
 
 
 
 
Specie
s 
Data Alterna
tive 
Splicin
g 
Gene 
family 
size 
Bias 
control 
Correlation  Ref. 
Human Ensemb
l 
ASD's 
AltSplic
e 
databas
e 
BLSA
TP 
Exons, 
EST 
coverage, 
gene 
family size, 
isoform 
count 
Negative correlation, decreased AS 
percentage  
Kopelman et 
al. 2005 
 NCBI, 
UCSC 
GeneSp
licer 
program 
EnsMa
rt 
Remove 
garbage 
EST, EST 
coverage,  
Negative correlation, increased no 
AS percentage 
Su et al. 2006 
 
 
 
H-
InvDB 
5.0 
H-
InvDB 
5.0 
BLAS
T 
 Duplicates with higher AS 
percentage, decreased AS 
percentage in duplicates 
Jin et al. 2008 
Mouse  Ensemb
l 
ASD's 
AltSplic
e 
databas
e 
BLSA
TP 
exons, EST 
coverage, 
gene 
family size, 
isoform 
count 
Negative correlation, decreased AS 
percentage 
Kopelman et 
al 2005 
 NCBI, 
UCSC 
GeneSp
licer 
program 
EnsMa
rt 
Remove 
garbage 
EST, EST 
coverage,  
Negative correlation, increased no 
AS percentage 
Su et al. 2006 
 Riken's 
FANTO
M3 
Riken's 
FANTO
M3 
BLAS
T 
 Duplicates with higher AS 
percentage, decreased AS 
percentage in duplicates 
Jin et al. 2008 
C.elega
ns 
WormP
ep 
WormP
ep 
BLAS
TCLU
ST 
 Significant difference, decreased AS 
percentage 
Hughes & 
Friedman 
2008 
Rice TIGR 
4.0 
PASA 
program 
Pfam 
HMM 
& 
BLAS
TP-
based 
domai
ns 
Remove 
genes that 
lack 
transcript 
evidence 
Multi-gene family have more AS 
percentage than singletons with  
Significant difference 
Lin et al. 
2008 
Arabid
opsis 
TAIR7 TAIR7 TAIR7  Multi-gene family have more AS 
percentage than singletons with  
significant difference 
Lin et al. 
2008 
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Table S2: The source of genomes, predicted genes and ESTs. 
Tax ID Species 
Genome & Predict 
gene Version 
4530 Oryza sativa Ensembl MSU6 
3702 Arabidopsis thaliana Ensembl TAIR9 
6239 Caenorhabditis elegans Ensembl WS190.54 
7227 Drosophila melanogaster Ensembl BDGP5.4.54 
7668 
Strongylocentrotus 
purpuratus NCBI Spur_2.1 
7739 Branchiostoma floridae JGI JGI2.0 
7719 Ciona intestinalis Ensembl JGI2.55 
7955 Danio rerio Ensembl Zv8.55 
69293 Gasterosteus aculeatus Ensembl BROADS1 
8090 Oryzias latipes Ensembl HdrR 
8364 Xenopus tropicalis Ensembl JGI4.1.54 
9031 Gallus gallus Ensembl WASHUC2.54 
9823 Sus scrofa Ensembl Sscrofa9 
9913 Bos taurus Ensembl Btau_4.0 
10116 Rattus norvegicus Ensembl RGSC3.4.55 
10090 Mus musculus Ensembl NCBIM37 
9606 Homo sapiens Ensembl NCBI36.54 
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Table S3 Comparison of AS occurrence between singletons and duplicates 
  
Organism 
Singleton  
gene 
AS 
percentage 
Average 
AS 
Duplicate 
gene 
  
AS 
percentage 
Average 
AS 
P value 
(Mann-
Whitney 
test) 
Oryza sativa 2608 50.12% 1.18 11008 44.61% 1.02 3.44E-05 
Arabidopsis 
thaliana 2289 33.16% 0.64 10151 29.64% 0.57 0.0370 
Caenorhabditis 
elegans 1951 24.30% 0.51 2568 26.48% 0.63 0.0012 
Drosophila 
melanogaster 2400 38.92% 0.92 3012 40.77% 1.08 0.0052 
Strongylocentrotus 
purpuratus 546 21.98% 0.69 493 23.53% 0.77 0.1402 
Branchiostoma 
floridae 803 32.00% 0.81 577 32.41% 0.94 0.8614 
Ciona intestinalis 2192 51.82% 1.42 2925 52.17% 1.41 0.8312 
Danio rerio 2260 54.96% 1.32 6385 54.46% 1.45 0.0464 
Gasterosteus 
aculeatus 452 55.09% 1.33 1290 58.91% 1.50 0.0904 
Oryzias latipes 1000 51.20% 1.03 1817 48.65% 1.03 0.6083 
Xenopus tropicalis 1705 63.23% 1.66 3560 57.95% 1.63 0.0663 
Gallus gallus 2061 73.22% 2.30 3438 70.45% 2.29 0.2468 
Sus scrofa 1936 66.12% 1.83 3345 59.79% 1.72 7.20E-05 
Bos taurus 2626 74.07% 2.34 5794 70.61% 2.27 0.0084 
Rattus norvegicus 2252 65.59% 1.94 5413 64.66% 1.95 0.8630 
Mus musculus 3915 79.05% 3.01 9502 77.38% 2.91 0.0140 
Homo sapiens 3992 85.10% 4.54 9298 87.65% 4.73 0.0046 
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Table S4.  Correlation test between gene family size and AS occurrence using 
randomized AS. 
 
Organism 
All 
Genes P R Duplicates P R 
Oryza sativa 13616 3.73E-09 -0.0505 11008 6.04E-13 -0.0685 
Arabidopsis 
thaliana 12440 0.0629 -0.0167 10151 0.0872 -0.0170 
Caenorhabditis 
elegans 4519 0.0034 0.0435 2568 0.2422 -0.0231 
Drosophila 
melanogaster 5412 0.1935 0.0177 3012 0.0011 -0.0597 
Strongylocentrotus 
purpuratus 1039 0.1211 0.0481 493 0.6704 0.0192 
Branchiostoma 
floridae 1380 0.1747 0.0366 577 0.7317 0.0143 
Ciona intestinalis 5117 0.5466 0.0084 2925 0.0079 0.0491 
Danio rerio 8645 0.0286 0.0235 6385 0.8371 -0.0026 
Gasterosteus 
aculeatus 1742 0.1773 0.0323 1290 0.9708 0.0010 
Oryzias latipes 2817 0.1125 -0.0299 1817 0.0011 -0.0765 
Xenopus tropicalis 5265 0.1127 -0.0219 3560 0.0132 -0.0415 
Gallus gallus 5499 0.9370 -0.0011 3438 0.6009 -0.0089 
Sus scrofa 5281 0.0135 -0.0340 3345 0.1464 -0.0251 
Bos taurus 8420 0.0108 -0.0278 5794 6.90E-05 -0.0523 
Rattus norvegicus 7665 0.5257 -0.0072 5413 2.42E-05 -0.0574 
Mus musculus 13417 1.94E-05 -0.0369 9502 3.82E-32 -0.1206 
Homo sapiens 13290 0.0015 -0.0276 9298 8.38E-28 -0.1130 
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4 Transcript diversification by gene duplication and 
alternative splicing accounts for complexity increases 
over eukaryotic evolution 
4.1 Introduction 
Despite two rounds of genome duplication at the base of the vertebrate lineage 
(Ohno 1970; Dehal and Boore 2005), our genome contains almost as many genes as a 
worm (Lander et al. 2001). Alternative splicing (AS), is a post-transcriptional process in 
eukaryotic organisms by which multiple distinct transcripts are produced from a single 
gene, and as such it has the potential to boost the total number of distinct proteins 
encoded in a genome (Nilsen and Graveley 2010). Recent deep sequencing analyses in 
the human transcriptome have shown that over 90% of multi-exon genes undergo 
alternative splicing (Pan et al. 2008; Wang et al. 2008) and AS has been proposed as a 
potential determinant of organism complexity (Xing and Lee 2006). Efforts to assess 
alternative splicing variation among species have resulted in conflicting results partly 
because of the large differences in transcript coverage between genes and organisms 
(Brett et al. 2002; Heebal Kim 2004; Kim et al. 2007a; Takeda et al. 2008; Mollet et al. 
2010). Thus, the contribution of AS to transcript diversity and complexity throughout 
evolution remains unknown (Nilsen and Graveley 2010). 
Here we assess the prevalence of AS in 18 eukaryotic genomes that have diverged 
from the lineage leading to humans over the last 1.4 billion years. We then estimated 
overall transcript diversity to examine how it relates to organism complexity and other 
previously described genomic correlates of complexity. 
4.2 Materials and methods 
4.2.1 Data sources 
Genome sequences and annotations were obtained from sources in Table S1. Full 
mRNA and EST sequences were downloaded from UniGene (Sayers et al. 2009). Cancer 
derived EST libraries for human and mouse were removed from all analyses presented. 
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4.2.2 Identification of alternative splice events  
To estimate AS events in different organisms, a novel procedure was applied as 
follows:  
(1) Mapping predicted genes and ESTs to Genome and grouping ESTs for each 
gene. Overlapping and nested genes were identified and removed from further analyses. 
GMAP (Wu and Watanabe 2005) was used to align full transcripts and high quality ESTs 
to their corresponding predicted genes. Genes with no matching transcript were removed.  
(2) Template building. To obtain an exon template as complete as possible (as 
well as overcoming the fact that some invertebrates do not have full transcripts 
sequenced) full transcripts and ESTs were overlaid onto the genomic sequence (Figure 
S1). This was done as follows: First the longest partial or full transcript available forms 
the base of the template. All other mRNAs and ESTs are then aligned to the genomic 
sequence and boundaries with the previously included transcripts are revised to extend 
exons or include new ones. If a transcript only encompasses a single exon then it will be 
discarded. This allows identifying and discarding any single exon nesting genes which 
have not been previously annotated. 
(3) Detecting AS events. We developed an algorithm to compares the exon 
boundaries of any transcript to its corresponding template. Discrepancies of less than 15 
bp in length were discarded. We identified eight types of AS events (Figure S2).  
(4) Obtaining comparable AS data across genes and species. In order to avoid 
coverage biases, one hundred samples of 10 randomly selected transcripts were obtained 
per gene in every species. AS levels and isoform number were then calculated as 
described above in each sample and results were averaged per gene. 
(5) Identification of AS isoforms. To identify AS isoforms, transcripts were first 
sorted according to the number of AS events they contain. Then transcripts containing 
identical or similar AS events were classed as redundant and excluded from the analysis. 
The number of remaining transcripts was taken as estimate of AS isoforms produced per 
gene.  
 (6) Estimating total number of isoforms produced per gene. AS isoforms were 
calculated for all genes with over 100 transcripts available. These numbers were then 
correlated with those obtained from 10 transcript samples. The resulting regression 
equation for each species was then used to extrapolate isoform number from the 10 
transcript samples to an estimated number of total isoform number produced per gene 
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(Figure S3 and Table S3). For species with less than 100 genes with over 100 transcripts, 
the equation of a close relative was used instead: ciona’s for sea urchin and amphioxus, 
medaka’s for stickleback genes. As chicken AS levels are closer to those of mammals, 
lizard’s AS was predicted with the zebrafish equation. Transcript diversity was estimated 
by multiplying average isoform number per gene with total gene number in each species 
after removing isoforms with internal stop codons. 
4.2.3 Identification of paralogs and orthologs 
Orthology and paralogy information was obtained from BioMart (Haider et al. 
2009). For sea urchin and amphioxus, BLASTP (Altschul et al. 1997) and InParanoid 
(Berglund et al. 2008) were used to assemble gene families and reconstruct orthology 
relations. We defined 3879 gene families with one or more genes that were present in at 
least three invertebrate and three vertebrate species. For randomization protocol, we used 
the number of gene family size, AS isoform and transcript diversity from these gene 
families, and run linear regression between the random value (gene family size, AS and 
transcript diversity, respectively) against divergence time (1000 times) in order to show 
their trends (slope of the regression) through the time.  
4.2.4 Function and structure prediction of AS isoform. 
To calculate the proportion of AS transcripts with stop codons, BLASTX 
(Altschul et al. 1997) was run to search transcripts ORF according to protein sequences, 
we then deduced amino acid sequences for each AS isoform. From the BLASTX 
alignment files, we further extracted amino acid sequences of AS area and stop codons 
were identified. As the levels of stop codons vary greatly even between closely related 
species due to differences in sequencing quality, stop codon presence in AS areas of 
transcripts were corrected by the number of stop codons in constitutively translated areas. 
To evaluate and characterize the functions and structure of AS, we used 
InterProscan which contains 14 applications for the prediction of protein domains 
(Zdobnov and Apweiler 2001), including Pfam for the prediction of protein domains 
(Bateman et al. 2004),  SignalP 3.0 for signal peptide predictions (Bendtsen et al. 2004) 
and TMHMM (Krogh et al. 2001) for the predictions of trans-membrane domains. 
PSORT II (Nakai and Horton 1999) was conducted for the sub-cellular localization signal 
predictions. Secondary protein structures were predicted by CLC Main Workbench 5.7, 
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which is based on extracted protein sequences from the protein databank 
(http://www.rcsb.org/pdb/). 
4.2.5 Intergenic space, average intron length, TE content and 
recombination rates 
For the relationship between intergenic space and AS, we adapted the method to 
calculate the intergenic space from a previous study (Nelson et al. 2004). Genome size 
and average intron length per gene were obtained from the gene information from 
Ensembl. Transposable elements data were downloaded from NCBI 
(ftp://ftp.ncbi.nih.gov/genomes/).  
 
4.3 Results and discussion 
4.3.1 AS prevalence has increased throughout evolution 
In order to assess whether alternative splicing levels have changed over time, we 
identified AS events for each gene in 18 eukaryotic genomes (species listed in Table S1) 
from all partial and full transcripts available (cancer libraries and other diseased tissue 
libraries available were removed from further analyses). To this end, all available 
transcripts were aligned to each gene. Using these alignments a full exon intron gene 
template was constructed resulting in the identification of previously un-annotated exons 
in all species analysed. Orphan exons not supported by any transcript aligned to any other 
exon in the gene were removed, as they are likely to represent unannotated exons of 
overlapping genes or nested single exon genes. All transcripts containing premature stop 
codons were also removed from further analyses. To minimise the strong dependence of 
AS detection on transcript coverage per gene (Brett et al. 2002; Kim et al. 2007a; Nilsen 
and Graveley 2010), we used a randomisation protocol (adapted from (Kim et al. 2007a); 
see methods) identifying alternative splicing events in 1000 samples of 10 transcripts. 
Genes with less than 10 transcripts were removed from further analyses. Our results show 
that if species are arranged according to divergence time from the lineage leading to 
humans (data from ref. (Hedges et al. 2006)) AS levels and the percentage of genes with 
at least one AS event detected (average from ten transcript samples) have increased over 
the last 1.4 billion years from virtually none in yeast to 94.8% of genes being 
alternatively spliced in humans (Figure 1). This increase in AS levels is consistent with 
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observations by Kim et al. (Kim et al. 2007a). Our results show a much higher AS 
prevalence in non-human species (36.5% ~68.0% for invertebrates and 68.0%~93.4% for 
vertebrates) than previous estimates (15% for invertebrates and 30-45% for vertebrates: 
(Kim et al. 2007a). Importantly, our assessment of AS levels using publicly available 
transcript data for human and Drosophila melanogaster resulted in a similar percentage of 
genes being identified as having alternative splicing as recent studies using high 
throughput sequencing technology (Pan et al. 2008; Wang et al. 2008; Graveley et al. 
2011). We also reject previous findings suggesting a low AS occurrence in birds (Chacko 
and Ranganathan 2009) as chicken’s AS levels are more similar to that of mammals than 
to its closer relative anolis lizard (Figure 1A and 1B and Table 1). 
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Figure 1. AS levels in 18 eukaryotic genomes and analysis of functional content. (A) 
AS prevalence in 18 genomes. (B) Average AS isoforms per gene. Species names are 
listed in Table S1. 
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Table 1. Summary statistics for AS analysis in 18 eukaryotic genomes. 
Species Gene # 
Transcripts 
per gene 
Genes with > 
10 transcripts 
AS genes 
(%)* 
AS 
isoforms 
AS isoforms 
(sampling) 
Proteome 
size 
Yeast 7000 6.8 431 - 0 1 
7000 
Nematode 19000 44.3 4519 42.8 0.65 1.95 
35358 
Mosquito 16000 36.8 4644 36.5 0.44 1.76 
27463 
Fruit fly 15000 78.1 5412 59.2 1.11 2.49 
35892 
Sea urchin 21000 28.4 986 36.7 0.82 2.11 
41958 
Amphioxus 21000 46.3 1361 50.2 1.25 2.20 
44766 
Ciona 16000 86.2 5117 68.0 1.31 2.32 
36192 
Medaka 21000 72.1 2817 68.0 0.91 1.86 
37265 
Stickeback 22000 41.4 1742 70.5 1.03 1.98 
40224 
Zebrafish 22000 72.3 8645 83.4 1.45 2.63 
55826 
Frog 20000 81.2 5265 86.0 1.51 2.53 
49230 
Lizard 21000 21.6 935 71.5 0.76 2.47 
51556 
Chicken 17000 38.3 5499 92.9 1.94 3.43 
54792 
Pig 22000 83.8 5281 91.6 1.65 2.74 
58080 
Cow 22000 67.2 8420 92.2 1.98 2.81 
58759 
Rat 23000 48.7 7665 90.6 1.73 3.07 
67788 
Mouse 23000 177.2 13417 93.4 3.31 3.28 
69297 
Human 23000 305.7 13290 94.8 6.62 4.22 
90919 
 
*  The AS percentage is the gene with at least 1 AS event out of 10 ESTs. 
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4.3.2 Contribution of alternative splicing and gene duplication to the 
transcript diversity 
Having shown that alternative splicing levels have increased along evolution we 
estimated the overall contribution of alternative splicing to transcript diversity per 
species. To this end, we first estimated the number of alternative splicing isoforms 
produced per gene within our sample (see methods). This AS level index was then 
translated into an estimate of actual AS isoform number produced per gene within a given 
species by extrapolating AS rates derived from genes with over 100 ESTs to the whole 
gene pool for that species (see methods; see Figure S3).  
Overall transcript diversity was then estimated by multiplying average isoform 
number per gene by total gene number in each species after removing transcripts 
containing premature stop codons (Table 1 and Figure 2, see methods). We found that 
while gene number has remained relatively stable in the last one billion years (note that 
bony fishes possibly underwent a whole genome duplication not shared by the terrestrial 
lineages (Jaillon et al. 2004; Kasahara et al. 2007), the contribution of AS isoforms to the 
transcript pool has increased from less than 1% in yeast to around 75% in human (Figure 
2). Notably, human displayed the largest transcript diversity with an estimate of 91000 
distinct transcripts (Figure 2 and Table 1). Similar AS and transcript diversity increases 
are found when restricting the analyses to the set of 3879 orthologous gene families 
present in both invertebrate and vertebrate species (see methods; Figure S4). Using a 
randomization protocol (see methods) we find that whereas only 40% of gene families 
have increased their gene number by gene duplication (slope > 0), over 80% of gene 
families have increased their number of AS isoforms, both contribute to the expansion of 
transcript diversity (Figure 3). 
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Figure 2. Evolution of gene number, AS and proteome size. Upper panel shows 
relative contribution of gene number and alternative splicing to proteome size for 
species grouped by their divergence time from the human lineage (tree adapted from  
(Hedges et al. 2006)). Bottom panel presents gene number, average AS isoform 
number and proteome size as a function of time of divergence from the lineage 
leading to human. 
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4.3.3 Transcript diversity is a strong predictor of organism complexity 
Alternative splicing has been proposed to contribute to organism complexity thus 
explaining the relatively stable gene number since the divergence of the vertebrate lineage 
from protostomians (Nilsen and Graveley 2010). In order to assess the relationship 
between estimated transcript diversity and organism complexity we compared transcript 
diversity estimates against organism complexity –assayed as total cell type number per 
species (Valentine et al. 1994). We found that while gene number and splicing isoforms 
contribution to transcript diversity are significantly related with complexity (R2 = 0.499, P 
= 0.0010 and R2 = 0.696, P = 1.667e-05, respectively), total transcript diversity per 
species is a better predictor of cell type number (R2 = 0.749, P = 4.372e-06; Figure 4). 
Similar results were obtained when analysing orthologous gene families (for gene 
number, R2 = 0.582, P = 0.0006; alternative splicing R2 = 0.611, P = 0.0001 and transcript 
diversity, R2 = 0.786, P = 9.404e-07; Figure S5).  
Interestingly, the larger human EST pool compared to other mammals is not 
reflected in a proportionally higher cell type number. This may result from the lack of 
resolution in cell type estimates among mammalian species or may reflect the significant 
higher brain to body weight ratio particular to our species of 7.6 compared to 0.5 in the 
other four mammalian species analysed (Roth and Dicke 2005). Future analyses will 
allow testing this hypothesis. 
 
 
 
Figure 3. Simulation of the changes of gene duplication (left), transcript diversity 
(middle) and alternative splicing (right) in 3879 gene family through divergence time 
(1000 times randomization).  
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4.3.4 Transcript diversity is a better predictor of organism complexity 
than any previously reported co-varying parameters 
So far we have shown that overall transcript diversity is strongly correlated with 
organism complexity. But how does it compare with other reported genomic predictors of 
organism complexity? Previous reports have shown that organism complexity is 
associated with proliferation of a variety of genomic features such as genome size, total 
gene number, intron and intergenic spacer length and transposable element (TE) content 
(Lynch and Conery 2003). To test the contributions of each parameter to organism 
complexity we used a forward stepwise regression analyses (F = 4.0) and found that 
transcript pool size is the only relevant predictor of complexity. Increases in functional 
domains have also been proposed as a contributor to complexity (Vogel and Chothia 
2006; Xia et al. 2008b). We identified functional content per gene using functional 
component prediction software (for list see Table S2). We found that while a number of 
functional content parameters are related to complexity, transcript diversity explains the 
most variance. Using a stepwise regression analyses (F = 4.0) including all 12 functional 
component indexes as well as transcriptome pool size (Table S2), we found that transcript 
diversity is the main predictor of cell type number explaining 75% of the variance in cell 
type number with HMMPfam and PatternScan explaining a further R2 = 0.0721 and 
0.0486 (P < 0.0001). This suggests that evolution of complexity has been accompanied by 
increases in the number of distinct transcripts with only minor changes in the functional 
content of peptide sequences consistent with limitations on functional domain 
interference (Innan and Kondrashov 2010).  
In summary, taking advantage of the increasing availability of transcript data for a 
variety of species and using a random sampling protocol to address biases due to 
differential transcript coverage we have shown that AS has increased steadily over the 
last 1.4 billion years. Most importantly perhaps, our estimates of transcript pool size 
explain over 75% of cell type number variance making it a far better predictor of 
complexity than any previously reported genomic predictor of complexity. 
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Figure 4. AS, complexity and functional gene associations. Correlation of Cell type 
number (data from ref. (Valentine et al. 1994)) with gene number, AS and estimated 
proteome size per species. Regression lines and coefficients are shown (P = 0.0010, 
1.667 X10-5 and 4.372 X10-6 as labels appear in graph). 
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 Table 2. Complexity, effective population size and genomic features 
Million 
years 
ago Species 
Genome 
size 
Intergenic 
space Log2(Neu)* 
Cell 
type 
TE  
(%) 
Average 
intron 
length 
Average 
number 
of exon 
0 Human 3.3E+09 2.1E+09 11.66 210 44 4921.9 7.4 
91 Mouse 3.4E+09 1.9E+09 11.85 190 40 3721.2 6.8 
91 Rat 2.5E+09 2.1E+09 - 190 40 3392.0 7.3 
97 Pig 2.4E+09 1.8E+09 - 188  3677.2 8.0 
97 Cow 3.2E+09 2.0E+09 - 188 27 3301.9 8.5 
325 Chicken 1.1E+09 7.5E+08 - 172 9 2245.9 9.0 
325 Lizard 1.7E+09 8.9E+08 - 172  3441.6 9.1 
362 Frog 1.5E+09 7.6E+08 - 145 33 3016.2 7.8 
455 Zebrafish 1.6E+09 8.4E+08 - 128 26 2860.4 8.6 
455 Medaka 7.0E+08 5.3E+08 - 128  1428.7 9.9 
455 Stickleback 4.5E+08 2.6E+08 9.95 128 2.7 880.6 9.9 
774 Ciona 1.7E+08 7.1E+07 8.36 60 11 549.7 6.9 
774 Amphioxus 5.8E+08 2.7E+08 - 60 30 1409.0 8.4 
842 Sea urchin 8.1E+08 2.0E+08 8.76 56  1206.2 6.8 
910 Mosquito 1.3E+09 7.8E+08 8.39 50 47 2553.8 3.7 
910 Fruit fly 1.7E+08 1.0E+08 8.06 50 15 862.0 4.0 
910 Nematode 1.0E+08 4.6E+07 8.25 50 6 233.7 5.6 
1368 Yeast 1.2E+07 3.4E+06 5.45 10 3 72.3 1.0 
* Neu: the product of effective population size and the mutation rate. 
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4.4 Supplementary Materials 
Figure S1. The same with the Figure S1 in page 27. 
Figure S2. The same with the Figure S2 in page 28. 
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Figure S3. Linear relationship between AS index, total AS isoform number per gene 
for each species. Panels show the regression lines between AS index (as calculated 
with 10 ESTs sampling method) and AS isoform number for genes with at least 100 
ESTs for invertebrate and vertebrate species. 
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Figure S4. Evolution of alternative splicing, gene number and transcript diversity 
per gene family. Changes in gene number, average AS isoform number and 
transcript diversity in 3879 orthologous gene families present in at least three 
invertebrate and three vertebrate species as a function of estimated divergence time 
from the lineage leading to human. 
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Figure S5. Relation between gene number, average AS isoforms and transcript 
diversity in 3879 orthologous gene families (present in at least three invertebrate and 
three vertebrate species). Regression lines and coefficients are shown in each panel 
(P = 0.0001, 1.6e-05 and 9.404e-07). 
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Table S1. Species list with genome and transcript data sources. 
Tax ID Species Ab. 
Genome sequence & 
gene annotations Version 
4932 
6239 
Saccharomyces cerevisiae 
Caenorhabditis elegans 
Sce 
Ce 
Ensembl 
Ensembl 
SGD1.01 
WS190.54 
7227 Drosophila melanogaster Dm Ensembl BDGP5.4.54 
7159 Aedes aegypti Aae Ensembl AaegL1 
7668 
Strongylocentrotus 
purpuratus Spu NCBI Spur_2.1 
7739 Branchiostoma floridae Bfl JGI JGI2.0 
7719 Ciona intestinalis Cin Ensembl JGI2.55 
7955 Danio rerio Dr Ensembl Zv8.55 
69293 Gasterosteus aculeatus Gac Ensembl BROADS1 
8090 Oryzias latipes Ola Ensembl HdrR 
8364 Xenopus tropicalis Xt Ensembl JGI4.1.54 
28377 Anolis carolinensis Aca Ensembl  AnoCar1.0  
9031 Gallus gallus Gg Ensembl WASHUC2.54 
9823 Sus scrofa Ss Ensembl Sscrofa9 
9913 Bos Taurus Bt Ensembl Btau_4.0 
10116 Rattus norvegicus Rn Ensembl RGSC3.4.55 
10090 Mus musculus Mm Ensembl NCBIM37 
9606 Homo sapiens Hs Ensembl NCBI36.54 
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Table S2. Linear regression of average functional content per 100 amino acids 
versus cell type number 
 
 
 
Application P R2 
HMMPanther 0.0058 0.4079 
Gene3D 0.1459 0.1356 
HMMPfam 0.0057 0.4096 
Superfamily 0.0968 0.173 
ProfileScan 0.4255 0.0428 
HMMSmart 0.9296 0.0005 
PatternScan 0.5143 0.0289 
FPrintScan 0.0913 0.1783 
SignalPHMM 0.8385 0.0029 
TMHMM 0.595 0.0193 
Secondary structure 0.2989 0.0717 
Stop Codon 0.0036 0.4414 
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Table S3. Coefficients for regression equations of AS isoform number as a function 
of AS index from 10-transcript sampling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AS isoform 
Species 
*Genes with  
100~200 
transcripts a*x b R2 
Caenorhabditis elegans 209 0.816 0.636 0.333 
Drosophila melanogaster 174 0.353 0.645 0.327 
Aedes aegypti 827 0.385 1.252 0.359 
Strongylocentrotus 
purpuratus 
23 0.594 0.831 - 
Branchiostoma floridae 84 0.594 0.831 - 
Ciona intestinalis 580 0.594 0.831 0.509 
Danio rerio 166 0.642 0.438 0.523 
Gasterosteus aculeatus 88 0.642 0.438 - 
Oryzias latipes 647 0.687 1.079 0.423 
Xenopus tropicalis 505 0.5 1.069 0.321 
Anolis carolinensis 1 0.687 1.079 - 
Gallus gallus 157 0.906 1.35 0.449 
Sus scrofa 528 0.499 1.246 0.329 
Bos Taurus 777 0.575 1.099 0.462 
Rattus norvegicus 487 0.587 1.443 0.328 
Mus musculus 3326 0.62 1.441 0.406 
Homo sapiens 2864 0.686 1.988 0.436 
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5 Cancer associated transcript quality modifications 
by alternative splicing 
5.1 Introduction 
Cancer cells are associated with profound changes at the transcriptome level with 
hundreds of genes being up or down regulated when compared to normal tissues 
(Martinez et al. 2010). Transcription profiling of cancer samples has led to an increased 
understanding of cancer physiology and the identification of a number of transcriptional 
cancer markers. Alternative splicing (AS) is a post-transcriptional process in eukaryotic 
organisms by which multiple distinct functional transcripts are produced from a single 
gene. It is now known that most human genes undergo alternative splicing (Pan et al. 
2008; Wang et al. 2008). Several studies have explored cancer related changes in 
alternative splicing patterns (reviewed in (Kalnina et al. 2005; Venables 2006; Skotheim 
and Nees 2007; Wang and Cooper 2007b) resulting in the identification of an increasing 
number of cancer-specific AS events in a variety of cancer tissues (Xu 2003; Hui et al. 
2004; Parker et al. 2004; Kim et al. 2008b; He et al. 2009). Given the high number of AS 
events unique to cancer transcriptomes, cancer-specific transcripts have been proposed to 
play a key role in cancer physiology (Skotheim and Nees 2007; He et al. 2009). 
Nevertheless, only a handful of cancer-specific alternative splicing events have been 
experimentally validated (Wang et al. 2003; Hui et al. 2004). Given that a significant 
proportion of alternatively spliced transcripts result from noisy splicing in normal human 
tissues (Green et al. 2003; Lewis et al. 2003; Zhang et al. 2009; Pickrell et al. 2010), it is 
possible that most cancer-specific AS result from aberrant splicing in these abnormal cells 
and not play any significant role in cancer onset or progression (Xu 2003; Skotheim and 
Nees 2007; Kim et al. 2008b). Here, by examining human and mouse EST libraries we 
ask whether cancer transcriptomes show any differences in transcript quality compared to 
normal tissues. 
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5.2 Materials and methods 
5.2.1 Data sources 
Sequence and genome annotations were obtained from Ensembl. EST sequences 
and library information were downloaded from UniGene (Sayers et al. 2009). 
 
Table 1 Summary of transcripts from normal and cancer state 
Species 
name 
Disease 
state 
Tissue 
type 
Development 
stage 
Library 
count 
EST 
count 
Human Normal 37 7 297 1687320 
 Cancer 34 5 362 920844 
Mouse Normal 29 15 164 628506 
 Cancer 14 4 45 148156 
 
5.2.2 Identification of alternative splice events  
To estimate AS events in different organisms, a novel procedure was applied as 
follows: (i) Mapping predicted genes and ESTs to Genome and grouping ESTs for each 
gene. Overlapping and nested genes were identified and removed from further analyses. 
GMAP (Wu and Watanabe 2005) was used to align full transcripts and high quality ESTs 
to their corresponding predicted genes. Genes with no matching transcripts were removed 
from further analyses. (ii) Template building. To obtain a gene template as complete as 
possible, full transcripts and ESTs were overlaid onto the genomic sequence. This was 
done as follows: First the longest partial or full transcript available forms the base of the 
template. All other mRNAs and ESTs are then aligned to the genomic sequence and 
boundaries with the previously included transcripts are revised to extend exons or include 
new ones. If a transcript only encompasses a single exon then it will be discarded. This 
allows identifying any single exon which has not been previously annotated and 
discarding any non-supported exons annotated in the “predicted gene”. (iii) Detecting AS 
events. We developed an algorithm for AS event detection to compare the exon 
boundaries of any transcript to its corresponding template. Discrepancies of less than 15 
bp in length were discarded. To identify AS isoforms, transcripts were first sorted 
according to the number of AS events they contain. Then transcripts containing identical 
or similar AS events were classed as redundant. Each AS event was classified depending 
on whether it derives from cancer or normal libraries. Those AS events not found in either 
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normal or cancer libraries were deemed cancer or normal specific respectively, while AS 
events shared in both normal and cancer libraries were defined as normal common and 
cancer common respectively.  
 
 
 
Figure 1. Schematic representation of the proportion of transcripts containing 
alternative splicing events common in both normal and cancer libraries, or 
cancer/normal specific. First number in each label represents the total number of 
distinct AS events detected and the second the number of genes represented for 
human (Hs) and mouse (Mm). 
 
5.2.3 Identification of premature stop codons, functional and structural 
protein components per AS event 
As transcripts supporting the same AS event may contain premature stop-codon 
causing mutations, stop codon presence was characterised and counted on a per transcript 
basis. Other features such as functional components were jointly analysed for each 
splicing event. To calculate the proportion of AS transcripts with stop codons, BLASTX 
(Altschul et al. 1997) was run to search for ORFs according to protein sequences. From 
the BLASTX alignment files, amino acid sequences of the AS area were extracted and 
stop codons were identified and counted. To functionally characterize AS events, we used 
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InterProScan which contains 14 applications for the prediction of protein domains 
(Zdobnov and Apweiler 2001), including Pfam for the prediction of protein domains 
(Bateman et al. 2004), SignalP 3.0 for signal peptide predictions (Bendtsen et al. 2004) 
and TMHMM (Krogh et al. 2001) for the predictions of transmembrane domains. PSORT 
II (Nakai and Horton 1999) was used to identify the likely sub-cellular localization of 
protein products. Secondary protein structures were predicted by CLC Main Workbench 
5.7, which is based on extracted protein sequences from the protein databank 
(http://www.rcsb.org/pdb/). 
 
 
Figure 2. Premature stop codons in normal and cancer AS events. Top panel shows 
the percentage of premature stop codon containing AS events for normal and cancer 
tissues subdivided into those containing AS events unique to normal / cancer 
libraries or found in both. Bottom panel shows average number of premature stop 
codons with events divided in the same way as top panel. Stars represent significant 
differences among groups from top panels (Chi-square test) and bottom panels 
(Wilcoxon test) with 0.01< P < 0.05 (*), 0.001< P< 0.01 (**) and P <= 0.001 (***). 
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5.3 Results 
5.3.1 Identification of cancer-specific alternative splicing events in 
human and mouse 
A total of 10,896,836 ESTs for human and mouse were downloaded from 
UniGene (Sayers et al. 2009). Of these 3,384,826 ESTs had a clear disease state 
annotation and were split into 297 libraries representing normal 37 tissues and 362 cancer 
libraries for 34 tissues for human, 164 normal libraries corresponding to 29 normal tissues 
and 45 cancer libraries from 14 tissues for mouse (see Table 1). To identify alternative 
splicing events, a complete exon template was constructed for each gene by mapping all 
partial and full transcripts available (using Gmap software (Wu and Watanabe 2005)). 
Known nested genes as well as orphan exons, not present in any transcript extending 
beyond them, were removed from further analysis. Individual ESTs were then aligned to 
the resulting gene template to identify AS events. We identified a total of 1,349,341 and 
271,491 AS transcripts containing AS events for human and mouse respectively. Of 
these, a total of 1,259,641 (93.3%) and 199,943 (73.6%) for human and mouse 
respectively were found in both normal and cancer libraries while 23,876 (1.8%) and 
1,956 (0.7%) were found only in cancer libraries. The remainder 65,824 (4.9%) and 
69,592 (25.6%) transcripts were found to contain AS events exclusive to normal tissue 
derived libraries (Figure 1). The higher percentage of normal-specific AS events in mouse 
is explained by the limited cancer transcripts available for this species (Table 1). 
73 
 
Figure 3. Identifiable functional components in AS events in cancer and normal 
tissues. Top panel shows the percentage of AS events with at least one identifiable 
functional component (see methods). Bottom panel shows average number of 
identifiable functional components per AS area. In both panels transcripts were 
divided as in Figure 2. Stars represent significant differences among groups from 
Wilcoxon tests with 0.01< P < =0.05 (*), 0.001< P<= 0.01 (**) and P <= 0.001 (***). 
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Figure 4. Normal and cancer specific AS events frequency distributions. Top panel 
shows the number of times each AS event is found and bottom panel shows the 
number of libraries where an AS event is found. Error bars in distributions from 
normal specific transcripts represent one hundred randomly selected samples from 
normal-specific transcripts of equal transcript and library number to the number of 
cancer-specific transcripts and libraries available. 
 
 
 
5.3.2 Cancer transcripts show signatures consistent with splicing noise 
We then assessed whether cancer libraries and in particular cancer-specific 
transcripts show signatures consistent with increased rates of splicing noise. If so, we 
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expect cancer transcripts to: A) have a higher incidence of nonsense or frameshift 
mutations which introduce a premature translation termination codons to mRNAs 
resulting in truncated proteins or more often rendering them vulnerable to nonsense 
mediated decay (NMD) (Green et al. 2003; Lewis et al. 2003). In the case of cancer-
specific transcripts we can expect them to: B) have reduced identifiable functional 
components consistent with higher rates of aberrant incorporation of non coding regions 
into the transcript (see methods); C) be found mostly as single copy and D) be present in 
only one library thus not being part of the core cancer transcription profile as these are 
more likely to result from splicing errors (Zhang et al. 2009). 
Transcripts were classified according to whether they contained AS events found 
in both normal and cancer tissues or unique to either resulting in four groups: 1) Normal 
common, with transcripts containing AS events also found in at least one cancer library, 
2) Normal-specific, whose AS events are only found in normal tissue samples, 3) Cancer 
common, containing transcripts from cancer libraries with AS events also found in at least 
one normal tissue library and 4) Cancer-specific with transcripts with AS events unique to 
cancer libraries. Our results show, compared to normal tissue derived transcripts, an 
increased incidence of premature stop codons among cancer-derived transcripts which is 
higher for cancer-specific transcripts (Figure 2, P <0.0001) in both human and mouse. In 
both species, cancer-specific events were also found to have a significantly lower number 
of identifiable functional components (P < 0.0001; Figure 3). In addition, we found that 
the vast majority (79.0%) have been sequenced only once with 90.5% identified in a 
single EST library in human (Figure 4). In contrast, normal-specific transcripts show less 
pronounced differences in premature stop codons and functional components compared to 
transcripts with normal-common AS events (Figure 2 and Figure 3). We also found that 
transcripts containing AS events particular to normal tissues are significantly less likely to 
be found as a single copy or confined to a single library (P <= 0.0001; Figure 4).  
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Figure 5. Premature stop codon frequency in oncogenes, tumour suppressor and 
other genes. Top panel shows the percentage of premature stop codon containing AS 
events. Bottom panel shows the average number of stop codons per AS events. AS 
events were classified depending on whether they were derived from oncogenes 
tumour suppressor and other genes. Broader groupings from Figure 2 and Figure 3 
are also labelled. Stars represent significant differences among groups from top 
panels (Chi-square test) and bottom panels (Wilcoxon test) with 0.01< P < 0.05 (*), 
0.001< P< 0.01 (**) and P <= 0.001 (***). 
 
5.3.3 Tumour suppressor and oncogenes reveal contrasting transcript 
quality reductions in cancer libraries 
Because tumour suppressor and oncogenes play a key role in tumour progression, 
we tested whether these gene categories presented any differences in the frequencies of 
disabled transcripts. Inactivation of tumour suppressor genes NFI, FHIT and TSG101 and 
strengthening oncogenes CD44 and RON by AS have been reported (reviewed in 
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(Kalnina et al. 2005; Skotheim and Nees 2007). To test whether splicing noise signatures 
affect tumour suppressor and oncogenes differently, we divided all genes into oncogenes 
(648), tumour suppressor (850) and other genes according to the CancerGenes database 
(Higgins et al. 2007). We found that even if as a whole cancer-derived transcripts are 
more likely to contain premature stop codons consistent with misplicing (Figure 2), this 
increase is not equally distributed between gene categories (Figure 5). Common cancer-
derived oncogene transcripts show only marginal changes in the rate of premature stop 
codons compared with transcripts derived from normal tissues (Figure 5). In contrast, 
tumour suppressor genes show a marked increase in the incidence of premature stop 
codons in cancer libraries (Figure 5, P < 0.001). These differences in transcript quality 
among gene categories are not observed in normal libraries.  
 
 
Figure 6. AS event frequency for normal and cancer transcripts divided into 
oncogene, tumour suppressor and other genes. Left and right panels represent 
cancer-specific and normal-specific AS events, respectively. Distributions for 
normal-specific AS events are the average results from 100 randomly selected 
samples of equal size to the number of cancer-specific AS events. Top panels present 
the percentage of AS events which are present in more than one copy and/or more 
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than one library. Bottom panels are a box plot of the average number of copies per 
AS event or the number of libraries where each AS event is present. Stars represent 
significant differences among groups from top panels (Chi-square test) and bottom 
panels (Wilcoxon test) with 0.01< P < 0.05 (*), 0.001< P< 0.01 (**) and P <= 0.001 
(***). 
 
Analyses of transcripts specific to cancer or normal tissues showed that cancer-
specific AS events have an elevated rate of premature stop codons in all three categories, 
further suggesting that a significant proportion of cancer-specific AS events containing 
transcripts are likely to result from splicing errors. We also found an elevated frequency 
in premature stop codons among tumour suppressor derived normal-specific AS 
transcripts (Figure 5; P = 0.016 and P = 0.014) which is not explained by the fact that 
these genes have a slightly longer average coding region (Figure 1S and 2S). When 
comparing transcript abundance in cancer-specific AS events (Figure 6), we found that 
oncogenes are more likely to produce cancer-specific AS events with more than one copy 
and to be found in more than one library than other genes (P = 0.037; Figure 6). This 
pattern is not found for normal-specific AS transcripts where the group of other genes 
were far more likely to be present in multiple copies and multiple libraries than both 
tumour suppressor and oncogenes (P < 0.0001; Figure 6).  
In order to assess functional content, we examined the distribution of functional 
components for oncogenes, tumour suppressor and other genes in both cancer and normal 
AS transcripts. For alternative splicing events found in both cancer and normal libraries, 
oncogenes and tumour suppressor derived transcripts had higher frequencies of functional 
components compared to other genes (Figure 7, P = 0.008 and P = 0.04), suggesting that 
alternative splicing areas contribute significantly to the functional properties of these 
genes protein products.  While among normal-specific AS areas there is a reduction in the 
functional content from oncogenes; in cancer-specific AS areas, it is tumour suppressor 
genes which show a marked reduction in functional content. No such reduction is 
observed among AS areas of oncogenes (Figure 7, P = 0.019). 
 
5.4 Discussion 
We have shown that transcripts derived from cancer libraries have an elevated rate 
of stop codons consistent with increased rates of missplicing in cancer transcriptomes. 
Transcripts with alternatively splicing events unique to cancer libraries showed an even 
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greater enrichment in premature stop codons (Figure 2) as well as containing fewer 
identifiable functional domains (Figure 3). Importantly, all cancer-specific transcripts 
were found in fewer than ten cancer libraries (out of a total of 367) with almost 80% of 
them found as a single copy (Figure 4). These features suggest that a significant 
proportion of these transcripts are unlikely to produce a functional protein product and  
given that no cancer specific transcripts was found to be ubiquitous to all cancer libraries 
or even a cancer type, we believe that the majority of cancer-specific transcripts, although 
probably functional, are unlikely to form part of a core cancer-transcriptome. Thus we 
estimate that the clinical and diagnostic relevance of particular cancer-specific transcripts 
may prove rather limited. 
 
Figure 7. Identifiable functional components in AS events in cancer and normal 
transcripts divided into oncogene, tumour suppressor and other gene-derived. Top 
panel shows the percentage of AS events with at least one identifiable functional 
component (see methods). Bottom panel shows average number of identifiable 
functional components per AS area. In both panels, AS events were divided into 
groups as in Figure 3 and further subdivided into oncogene, tumour suppressor and 
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other genes. Stars represent significant differences among groups from top panels 
(Chi-square test) and bottom panels (Wilcoxon test) with 0.01< P < 0.05 (*), 0.001< 
P< 0.01 (**) and P <= 0.001 (***). 
In contrast, analyses of transcripts only found in normal tissue samples did not 
reveal a similar increase in noise signatures (Figure 2 and 3) and a significantly greater 
proportion were found in multiple libraries (Figure 4). Mutations leading to the absence 
of these transcripts in cancer libraries may have a role in cancer establishment and its 
progression and may therefore warrant further studies examining their clinical potential. 
Interestingly, when dividing genes into oncogenes, tumour suppressors and other 
genes, we found marginal increases in stop codons in oncogene derived transcripts in 
cancer libraries while tumour suppressor genes showed a strong increase in premature 
stop codons. We found a higher incidence of premature stop codons amongst tumour 
suppressor genes in both normal-specific and cancer-common AS (Figure 5). This is not 
explained by differences in coding region length (Figure S1 and S2). The fact that cancer-
specific oncogene transcripts have a higher functional content compared to those normal 
specific, suggests that, in some instances, oncogene-derived cancer-specific transcripts 
may confer novel functional properties to protein products potentially having a role in 
cancer cells. Given that this set of transcripts are mostly found in single libraries it is 
likely that their functional contribution is likely to be specific to cancers of individual 
patients. 
We conclude that cancer states are associated with an elevated rate of aberrant 
transcripts particularly pronounced in tumour suppressor genes but from which oncogenes 
are spared. We therefore suggest that splicing noise should be considered when 
evaluating cancer-specific splicing events as they have a significant higher incidence of 
premature stop codons. Given that nonsense mutations affect only a minority of 
transcripts, it is feasible to assume that most cancer and normal specific transcripts may 
be transcribed into functional proteins and may contribute significantly to the cancerous 
phenotype. Nevertheless, the fact that most cancer-specific splice variants we identified 
are found as single copies in one EST library may somewhat limit their value as wide 
spectrum diagnostic probes and/or treatment targets. Assessment of global AS signatures 
by gene category may be more promising. Finally we propose that the roles of normal-
specific and mutation in common alternative splicing variants should be examined in 
addition to cancer-specific transcripts; analyses of these absent AS transcripts may further 
aid in the understanding of the cancer physiology. 
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5.5 Supplementary Materials  
 
Figure S1: Comparison of the length of coding region among oncogene, other genes 
and tumour suppressor genes. The length of transcripts of tumour suppressor genes 
is significant longer than other genes and oncogene. Stars represent significant 
differences among groups (Wilcoxon test) with 0.01< P < 0.05 (*), 0.001< P< 0.01 
(**) and P <= 0.001 (***). 
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 Figure S2: Average number of stop codons per 100 amino acids in oncogene, 
tumour suppressor and other genes. Broader groupings from Figure 2 and Figure 3 
are also labelled. Stars represent significant differences among groups (Wilcoxon 
test) with 0.01< P < 0.05 (*), 0.001< P< 0.01 (**) and P <= 0.001 (***). 
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6 General discussion 
Over a decade has passed since the publication of the first draft of the human 
genome. Since then, thanks to the development of increasingly powerful sequencing 
technologies, genomes of species from most major taxa have been sequenced. However, 
we still have a very limited understanding of how genes are controlled and how they 
underline observed phenotypes. For the last three years, I have focused my efforts on the 
study of alternative splicing as a potential source of functional innovation in the genome 
through evolution and disease states.  
 
6.1 Alternative splicing database: ECCASED 
Alternative splicing events detection is currently mostly based on transcript 
sequencing or exon based microarray technology. Genome sequence based prediction of 
alternative splicing events and prediction of levels of splicing remain unreliable. 
Although numerous alternative splicing datasets for multiple species are available (Kim et 
al. 2007b; Lee et al. 2007; Bhasi et al. 2009; Koscielny et al. 2009a), none takes into 
account the well documented fact that AS detection is highly dependent on transcript 
coverage for genes within a genome or between species (Brett et al. 2002; Kan et al. 
2002; Kim et al. 2007a; Nilsen and Graveley 2010). The lack of comparable estimates of 
AS levels impose serious limitations on the interpretation of any analyses of AS levels 
and its relation to other genomic and phenotypic variables especially with expression 
levels or any parameter co-varying with it. In order to explore how alternative splicing 
has evolved through time I decided to construct a comparative resource for alternative 
splicing data. In Chapter 2, I presented the Eukaryotic Comprehensive & Comparable 
Alternative Splicing Events Database (ECCASED) based on the analyses of over 30 
million ESTs for 114 eukaryotic genomes, including protists (22), plants (20), fungi (23), 
metazoan (non-vertebrates, 29) and vertebrates (20). Using a uniform analyses pipeline 
for all species the ECCASED database provides both comprehensive identification of AS 
events based on all available ESTs per gene and a comparable AS index using a random 
sampling protocol thereby overcoming biases in AS detection caused by differential 
transcript coverage. This data was then linked to a functional annotation including GO 
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terms and expression patterns of genes. Orthology annotations were used to allow 
comparative analysis among different species. The ECCASED database represents the 
first assessment of AS patterns for over 70% of the 114 species included in it. Most 
importantly, by providing an AS index not biased by transcript coverage differences, 
ECCASED is the first resource to provide a comparable AS index allowing direct 
comparisons for multiple genes within and between species.  
Given its potential benefit for the wider scientific community a web interface has 
been built (http://bio.bdfield.com/eccased/index.php). At the moment the ECCASED 
database allows one to inspect all AS events detected for each gene in 114 species of 
eukaryotes. By providing a comparable measure of AS based in random samples the 
ECCASED database also allows to make direct comparisons of the levels of AS across 
genes within and between genomes. Over the next year I plan to further improve this 
database in three ways: First, I will use next generation sequences to complement longer 
reads from EST sequences. The shorter but more abundant RNA-seq reads will allow us 
to: 1) assess whether AS events detected in a single EST is likely to be a splicing error; 2) 
identify new AS events not found in EST sequences and 3) more accurately calculate the 
levels of expression of specific isoforms which contain unique AS events. Secondly, 
alignments of orthologous genes with AS annotations will allow to directly assess 
conservation of AS events. Thirdly, where data allows for it, I plan to add transcript 
abundance per tissue for each AS isoform. 
 
6.2 How does alternative splicing correlate to gene duplication 
Alternative splicing is a potential source of transcript diversity, in addition to gene 
duplication, it is relevant to explore the relationship between alternative splicing and gene 
family size. Recent studies had reported that in some eukaryotes alternative splicing is 
inversely correlated with gene family size suggesting that the two processes are to some 
extent mutually exclusive but it hints that an optimal transcript diversity per gene family 
exists and is dynamically maintained by either increased alternatively spliced isoform 
through time (Roux and Robinson-Rechavi 2011) or decreased AS after events of gene 
duplication (Su et al. 2006) or a combination of both. I believe that existing studies 
present a number of methodological flaws, most importantly, they fail to account for the 
differential EST coverage associated with high and low expression of genes resulting in a 
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strong association between EST coverage and detected splicing events. In Chapter 3, 
using a random sampling of a set number of ESTs per gene to identify AS events, we 
generated alternative splicing estimates which are comparable across different genes and 
species in 17 species from plants to mammals.  
My results of the analysis of gene family expansion and AS levels in 17 species 
along the eukaryotic tree shows that there is no consistent trend of an inverse relationship 
between AS and GFS, and that in those species where the pattern is observed, the amount 
of variance explained is very small. Instead, the marginal relationship between AS and 
GFS in some species appears to be the result of the strong relationship between AS and 
GFS with breadth of expression. However, when looking at the patterns of transcript 
diversity increases on a per gene family basis across species, it is clear that for gene 
families with an expanding total number of distinct transcripts, AS and GFS are positively 
correlated. AS and GFS are negatively correlated only in gene families where there is no 
increase in overall transcript diversity. This suggests that AS and GFS do appear to be 
coupled processes which work together in diversifying gene families and become 
antagonistic in those gene families with a stable number of transcripts being produced 
suggesting that in those there is an optimum transcript diversity level. 
 
6.3 Alternative splicing and gene duplication contributes to 
transcript diversity expansion in eukaryotes 
One of the most fascinating consequences of the proliferation of genome 
sequences and transcript data in increasing number of species is the fact that it allows, for 
the first time, to examine the relationship between genomic features and observed 
phenotypes. One of the most elusive phenotypes is the evolution of complexity as how to 
measure this phenotype is controversial in itself. What actually underpins the complexity 
remains enigmatic. Taking the estimated number of cell types as a proxy of complexity, 
several studies have reported a link between complexity and various genomic features. 
There are two main explanations for the evolution of organism complexity. First is that 
the increasing regulation with the stable gene number. For example, the increasing 
complexity of gene regulation (Warnefors and Eyre-Walker 2011), protein-protein 
interaction domains on organism and network complexity (Xia et al. 2008a) or 
epigenetics factors such as non-coding RNAs and DNA methylation (Costa 2008). 
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Second one is by expanding the number of distinct proteins produced in an organism. 
However, these two hypotheses could be overlapped. Alternative splicing, as a product of 
the regulation of gene expression, will generate more proteins, which will then increase 
the interaction between proteins and form more complicated network. Therefore, I believe 
that multiple factors and changes in regulation levels contributed to the increasing 
complexity through evolution. 
In Chapter 4, through the systematic analyses of over 27 million publicly available 
full and partial transcripts from 18 eukaryotic species, I provide evidence for a strong 
increase in alternative splicing over the last 1400 million years. Importantly, our 
proteome size estimates, ranging from ~7000 in yeast to ~90000 in human, closely covary 
with organism complexity –assayed as cell type number. Compared to genome size, gene 
number, non-coding DNA parameters and functional domain content previously shown to 
covary with complexity, proteome size is by far the strongest genomic-derived predictor 
of organism complexity, explaining over 70% of the variance. These results could suggest 
that proteome expansion fuelled by alternative splicing and gene duplication constitutes 
one of the fundamental components in the evolution of organism complexity. 
6.4 Alternative splicing in cancer 
Recent genome-wide analyses have detected numerous cancer-specific alternative 
splicing (AS) events (Wang et al. 2003; Xu 2003; Hui et al. 2004; Kim et al. 2008b; He et 
al. 2009). However, analysis of AS patterns in normal tissue derived transcript libraries 
have suggested that a significant proportion of detected AS events in fact result from 
instances of miss-splicing. Whether transcripts containing cancer-specific AS events are 
likely to be translated into functional proteins or simply reflect noisy splicing, thereby 
determining their clinical relevance, is not known. In Chapter 5, I show that consistent 
with a noisy splicing model, cancer-specific AS events generally tend to be rare, 
containing more premature stop codons and with less identifiable functional domains in 
human and mouse. Interestingly, common cancer-derived AS transcripts from tumour 
suppressor and oncogenes show marked changes in premature stop codon frequency 
differences with tumour suppressor genes exhibiting increased levels of premature stop 
codons whereas oncogenes have the opposite pattern. We conclude that tumours tend to 
have faithful oncogene splicing, a higher incidence of premature stop codons among 
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tumour suppressor and cancer-specific splice variants and suggest the importance of 
normal-specific and mutation in common alternative splicing variants. 
This study proves that the present of novel transcripts in a disease state is not 
necessarily a reflection of an important biological role. Instead, novel transcript isoforms 
may in most cases reflect the fact that even under normal conditions, splicing regulation 
is not perfect.  We believe that instances of novel transcript/proteins becoming integral to 
the cancer machinery are rare. However, I most stress that whether alternative splicing 
does play a key role in diseased transcriptomes including cancer remains unknown. 
Changes in the relative and absolute levels of non-aberrant alternative splicing variants 
compared to normal tissues might in fact be decisive in cancer progression and 
maintenance. In addition, it may well be that increases or decreases in AS noise itself on a 
genome wide basis or for a smaller subset also impacts on cell behaviour. As the 
increasing number of the complete DNA sequence of cancer genomes provide us a 
comprehensive perspective of how cancers have developed (Stratton et al. 2009; 
Meyerson et al. 2010), it will be possible to better assess whether changes in splicing 
regulation plays a significant role. If so, then simply measuring changes in overall 
expression levels per gene may turn out to be missing key information.  
 
 
6.5 General conclusion 
Alternative splicing as a source of novel transcripts without the need of gene 
duplication events has been seen as a potential key player in the evolution of the 
eukaryotic genome since the sequencing of the human genome revealed it to have around 
3 times as many genes as the humble baking yeast. Despite the increasing interest in 
alternative splicing, however, little is known about AS levels in but a few species. The 
difficulties in predicting AS events from genomic sequences alone, together with the fact 
that AS event detection is strongly influenced by transcript coverage of a gene, has 
undoubtedly slowed down the study of how alternative splicing has evolved over time, 
how AS is regulated, and how it may relate to other genomic features and crucially to 
phenotype. To facilitate comparative genomics studies of AS, I implemented a consistent 
algorithm for transcript analyses in over 100 eukaryotic species. Comparable AS data 
allowed me to address a number of evolutionary questions regarding the evolution of AS 
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and its implications for the evolution of transcript diversity and complexity. I first 
assessed in Chapter 3 how AS relates to gene duplication events and found that contrary 
to recent studies carried out in a small number of species, AS and gene duplication are not 
negatively correlated on a genome-wide basis. Instead an inverse relation is only 
observed among gene families with a stable number of transcripts. AS has been proposed 
to be the missing source of complexity given that the number of genes in the human 
genome was well below expectations. My results presented in Chapter 4 appear to support 
to the notion that AS play a very important role in increasing transcript diversity and 
complexity in eukaryotes. Finally, in Chapter 5, by comparing normal and cancer tissue-
derived transcript libraries I found that, contrary to previous suggestions, there is little 
evidence for cancer-unique AS transcripts playing an important role in cancer onset and 
progression as most cancer AS events were found to be single copy events and 
constrained to one library. Together my results provide some novel insights into the 
evolution of AS.  
The analysis of AS is limited by the availability of transcript sequences. With the 
increasing popularity of next generation sequencing the study of alternative splicing is 
likely to undergo a revolution (Mortazavi et al. 2008). The higher depth of sequencing of 
transcriptomes in human and other species has increased our understanding of AS event 
expression patterns in different tissues (Wang et al. 2008; Kang et al. 2011), 
developmental stages (Graveley et al. 2011) and epigenetic regulation (Shukla et al. 
2011). 
This increasing amount of data is aiding the development of better AS event and 
tissue expression pattern predicting methods, further increasing our ability of performing 
comparative analysis of AS in species with no significant transcriptome coverage. 
Machine learning has been applied to predict the tissues-specific AS pattern in mouse 
(Barash et al. 2010). However, understanding the splicing code and regulation of AS, 
which are essential for predicting the AS pattern, will still be key issues given that 
regulation of AS occurs at many levels (Luco and Misteli 2011). 
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6.6 Future studies 
I will now describe some ongoing projects in collaboration with both my PhD 
supervisor Dr. Urrutia and her group as well as with my postdoctoral supervisor Dr. 
Soranzo through which I expect to further my understanding of alternative splicing and its 
biological relevance.  
1. Does alternative splicing impact gene duplicate retention? 
Why do some duplicate genes survive while others are lost? After duplication, most 
extra gene copies soon accumulate disabling mutations and degrade, but some are 
retained. Over a dozen models have been proposed to explain fates of duplicate genes 
(reviewed in (Innan and Kondrashov 2010; Soskine and Tawfik 2010). One widely held 
model predicts that, after a duplication event, the accumulation of reciprocally 
complementary mutations disabling both duplicate copies of a gene plays an important 
role in the retention of duplicate genes with the immediate acquisition of a novel function 
being a rare event (Ohno 1970; Lynch and Conery 2000; Innan and Kondrashov 2010; 
Soskine and Tawfik 2010). There are no reported gene characteristics which would 
predispose any genes to be duplicated other than in cases where gene dosage increases are 
favorable. I hypothesize that alternative splicing may potentially increase the chances of 
subfunctionalisation events after duplication events since a relatively small number of 
substitutions may allow the reciprocal loss of AS isoforms in the two duplicate copies 
leading to subfunctionalisation. To test this, I decided to analyse gene duplicate retention 
after whole genome duplication events at the base of the vertebrate lineage. Preliminary 
analyses show that higher levels of ancestral alternative splicing in Ciona and amphioxus, 
significantly increases duplicate gene retention. Moreover, alternative spliced areas 
appear to have been reciprocally lost among duplicate copies. These observations suggest 
that alternative splicing shapes the survival chances of duplicate genes possibly by 
facilitating functional split between gene copies. If so, it would suggest that, at least in 
some cases, functional innovation and protein specialization precedes rather than arise 
from duplication events. In these cases, gene duplication would stabilise alternative 
splicing isoforms while facilitating the accumulation of novel splicing events in a cycle of 
increasing transcript innovation. 
 
2. Are the increased levels of AS throughout evolution functionally relevant? 
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A number of studies have indicated that alternative splicing levels per gene have 
increased over time. My own analysis using a larger dataset of 18 species which corrects 
for differences in transcript coverage has also shown that AS has been an important 
contributor to transcript diversity expansion in the eukaryotic genome. Various reports 
however, suggest that a significant number of AS transcripts contain premature stop 
codons and have thus been proposed to be the result of splicing errors (Green et al. 2003; 
Lewis et al. 2003; Zhang et al. 2009). A comparison of AS patterns among orthologous 
genes found, however, that about 9% percent of conserved AS events between human and 
mouse result in premature stop codon-containing transcripts possibly adding an extra 
layer of regulation to gene expression (Mudge et al. 2011). Thus, whether the expansion 
in AS events over time is functional remains to be known.  If alternative splicing 
increases along the phylogenetic tree are indeed functional we would expect these AS 
events to: A) have a lower incidence of internal stop codons (rendering them vulnerable 
to nonsense mediated decay (Green et al. 2003; Lewis et al. 2003)), B) have a relatively 
higher number of identifiable functional components consistent with lower rates of 
aberrant incorporation of non coding regions into the transcript (see methods); C) be 
found mostly as multi-copy rather than single copy occurrences; D) be present in more 
than one library and E) be conserved through evolution. 
Preliminary data suggests that AS events have increased over time even when 
removing all transcripts containing premature stop codons or found in less than three 
copies. Moreover, the number of identifiable functional components per 100bp of 
transcript, either in AS regions or in the gene as a whole, has not decreased over time. 
Together these results suggest that even if a significant proportion of AS transcripts may 
indeed not be functional there is no indication that this proportion is growing, thus 
cancelling out the effects of transcript diversification. 
 
3. Mapping genetic variation with alternative splicing in human genome and disease.  
While expression QTL (eQTL) studies have illuminated the location and impact of 
genetic variants affecting gene expression, such analyses do not take into account the fact 
that unequal expression level exists among exons within a gene due to alternative splicing 
(AS). Recently, it has been reported that 94% human multi-exon genes undergo AS, and 
that up to 50% of the mutations that cause human disease may alter the efficiency and 
pattern of splicing. Therefore, AS may provide a potential mechanism underlying both 
phenotypic diversity and disease susceptibility in human populations. However, to what 
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extent genetic variation affects AS, how to infer splicing modification (e.g. splicing QTL) 
from genome-wide association studies (GWAS), and how to map genetic variation with 
alternative splicing pattern and identify candidate genes with disease-related splicing, 
remain largely unexplored. We used data from ~ 8 millions ESTs and ~40 millions SNPs 
from the 1000 Genome Project in humans, to assess the relationship between SNPs and 
AS. We found a strong positive correlation between the number of SNPs and AS 
occurrence, with SNPs being enriched in the splicing site recognition sequence, or AS 
regulation domains, of AS exons compared to exons that are constitutively transcribed (p 
< 0.0001). We further systematically searched 5,786 disease/trait-related SNPs previously 
identified through GWAS (http://www.genome.gov/gwastudies/), and identified 16 SNPs 
located in splicing sites and 129 SNPs in splicing regulatory motifs. Our results provide 
initial evidence of a possible important role of sQTL in modulating genetic traits and 
diseases. We suggest that further work improving the bioinformatic interpretation of 
sQTLs will be crucial to understanding of the splicing code. To achieve this goal, we 
propose the first comprehensive splicing map for each exon in the human genome, and a 
database of both reported and predicted sQTLs, which will facilitate future sQTL studies 
in human disease. 
4. Alternative splicing in fungal species 
While alternative splicing has been intensively characterised in human where up to 
94% of multi-exon genes have been found to be alternatively spliced, little is known 
about this process in fungi. In baker’s yeast (S. cerevisiae), the most highly studied fungal 
species, alternative splicing has only been reported in a few genes such as Src1 (Grund et 
al. 2008) and PTC7 (Juneau et al. 2009). Prevalence and patterns of alternative splicing 
across different fungal taxa remains unknown. Here we assess alternative splicing in 23 
fungal species with sequenced genomes and over 30,000 EST transcript data. We are 
planning to investigate: 1) What is the prevalence of alternative splicing in fungal genes 
and variation across species? 2) What is the frequency of different types of alternative 
splicing to contrast with frequency? 3) How has alternative splicing evolved in different 
fungal lineages? 4) Are alternatively spliced transcripts in fungi functional? 
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